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A B S T R A C T
Background
Specific allergen immunotherapy (SIT) is a treatment that may improve disease severity in people with atopic eczema (AE) by inducing
immune tolerance to the relevant allergen. A high quality systematic review has not previously assessed the efficacy and safety of this
treatment.
Objectives
To assess the effects of specific allergen immunotherapy (SIT), including subcutaneous, sublingual, intradermal, and oral routes,
compared with placebo or a standard treatment in people with atopic eczema.
Search methods
We searched the following databases up to July 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane
Library (Issue 7, 2015), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), Web of Science™ (from 2005), the
Global Resource of EczemA Trials (GREAT database), and five trials databases. We searched abstracts from recent European and North
American allergy meetings and checked the references of included studies and review articles for further references to relevant trials.
Selection criteria
Randomised controlled trials (RCTs) of specific allergen immunotherapy that used standardised allergen extracts in people with AE.
Data collection and analysis
Two authors independently undertook study selection, data extraction (including adverse effects), assessment of risk of bias, and analyses.
We used standard methodological procedures expected by Cochrane.
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Main results
We identified 12 RCTs for inclusion in this review; the total number of participants was 733. The interventions included SIT in children
and adults allergic to either house dust mite (10 trials), grass pollen, or other inhalant allergens (two trials). They were administered
subcutaneously (six trials), sublingually (four trials), orally, or intradermally (two trials). Overall, the risk of bias was moderate, with
high loss to follow up and lack of blinding as the main methodological concern.
Our primary outcomes were ’Participant- or parent-reported global assessment of disease severity at the end of treatment’; ’Participant-
or parent-reported specific symptoms of eczema, by subjective measures’; and ’Adverse events, such as acute episodes of asthma or
anaphylaxis’. SCORing Atopic Dermatitis (SCORAD) is a means of measuring the effect of atopic dermatitis by area (A); intensity
(B); and subjective measures (C), such as itch and sleeplessness, which we used.
For ’Participant- or parent-reported global assessment of disease severity at the end of treatment’, one trial (20 participants) found
improvement in 7/9 participants (78%) treated with the SIT compared with 3/11 (27%) treated with the placebo (risk ratio (RR)
2.85, 95% confidence interval (CI) 1.02 to 7.96; P = 0.04). Another study (24 participants) found no difference: global disease severity
improved in 8/13 participants (62%) treated with the SIT compared with 9/11 (81%) treated with the placebo (RR 0.75, 95% CI
0.45 to 1.26; P = 0.38). We did not perform meta-analysis because of high heterogeneity between these two studies. The quality of the
evidence was low.
For ’Participant- or parent-reported specific symptoms of eczema, by subjective measures’, two trials (184 participants) did not find
that the SIT improved SCORAD part C (mean difference (MD) -0.74, 95% CI -1.98 to 0.50) or sleep disturbance (MD -0.49, 95%
CI -1.03 to 0.06) more than placebo. For SCORAD part C itch severity, these two trials (184 participants) did not find that the SIT
improved itch (MD -0.24, 95% CI -1.00 to 0.52). One other non-blinded study (60 participants) found that the SIT reduced itch
compared with no treatment (MD -4.20, 95% CI -3.69 to -4.71) and reduced the participants’ overall symptoms (P < 0.01), but we
could not pool these three studies due to high heterogeneity. The quality of the evidence was very low.
Seven trials reported systemic adverse reactions: 18/282 participants (6.4%) treated with the SIT had a systemic reaction compared
with 15/210 (7.1%) with no treatment (RR 0.78, 95% CI 0.41 to 1.49; the quality of the evidence was moderate). The same seven
trials reported local adverse reactions: 90/280 participants (32.1%) treated with the SIT had a local reaction compared with 44/204
(21.6%) in the no treatment group (RR 1.27, 95% CI 0.89 to 1.81). As these had the same study limitations, we deemed the quality
of the evidence to also be moderate.
Of our secondary outcomes, there was a significant improvement in ’Investigator- or physician-rated global assessment of disease severity
at the end of treatment’ (six trials, 262 participants; RR 1.48, 95%CI 1.16 to 1.88). None of the studies reported our secondary outcome
’Parent- or participant-rated eczema severity assessed using a published scale’, but two studies (n = 184), which have been mentioned
above, used SCORADpart C, which we included as our primary outcome ’Participant- or parent-reported specific symptoms of eczema,
by subjective measures’.
Our findings were generally inconclusive because of the small number of studies. We were unable to determine by subgroup analyses
a particular type of allergen or a particular age or level of disease severity where allergen immunotherapy was more successful. We
were also unable to determine whether sublingual immunotherapy was associated with more local adverse reactions compared with
subcutaneous immunotherapy.
Authors’ conclusions
Overall, the quality of the evidence was low. The low quality was mainly due to the differing results between studies, lack of blinding
in some studies, and relatively few studies reporting participant-centred outcome measures. We found limited evidence that SIT may
be an effective treatment for people with AE. The treatments used in these trials were not associated with an increased risk of local or
systemic reactions. Future studies should use high quality allergen formulations with a proven track record in other allergic conditions
and should include participant-reported outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Specific allergy immunotherapy for the treatment of atopic eczema
Background
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At least one in seven children and one in 50 adults suffer from atopic eczema, a skin condition characterised by an itchy red rash.
People with atopic eczema are allergic to things in the environment, such as house dust mites, and exposure to what they are allergic
to may make their eczema worse. Specific allergen immunotherapy is a treatment that involves a course of injections or drops under
the tongue containing the substance to which a person is allergic. The treatment can reduce the severity of a person’s allergy and may
therefore be able to reduce symptoms of atopic eczema. We evaluated whether specific allergen immunotherapy was better or worse
than a standard treatment or placebo at improving disease severity and symptoms as assessed by participants, parents, or investigators.
Review question
Is specific allergen immunotherapy an effective treatment for people with atopic eczema?
Study characteristics
The evidence is current to July 2015. We found 12 studies, with 733 participants, which included both children and adults. Studies were
conducted in specialist allergy centres in nine countries. The duration of trials ranged from four months to three years. Immunotherapy
was administered to the participants in four different ways. Allergen manufacturers funded seven of the 12 studies.
Key results
We found no evidence from the studies in our review that SIT may be an effective treatment for atopic eczema, as rated by participants
or parents for disease severity and symptoms. We found limited evidence that SIT may improve investigator-rated disease severity.
Immunotherapy did not cause any more harm than a standard treatment or placebo.
Quality of the evidence
Overall, the quality of the evidence was low. We downgraded quality mainly due to the differing results between studies, lack of blinding
in some studies, and that relatively few studies reported outcomes relevant to patients. Future studies should use high quality allergen
formulations with a proven track record in other allergic conditions and should include participant-reported outcome measures.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Specific immunotherapy compared with no immunotherapy for atopic eczema
Patient or population: adults and children with atopic eczema and inhalant allergen sensitisation
Settings: specialist allergy centres in the UK (2 trials), Italy (3 trials), USA, Germany, Belgium, Poland, Columbia, and China
Intervention: specific allergen immunotherapy
Comparison: no immunotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No immunotherapy Specific allergen im-
munotherapy
Participant- or parent-
reported global assess-
ment of disease severity
Follow-up: 6 to 12
months
See comments See comments Not estimable 44a
(2)
⊕⊕©©
lowb
Improvement in 7/9 par-
ticipants (78%) in the im-
munotherapy group and
3/11 participants (27%) in
the placebo group (RR 2.
85, 95% CI 1.02 to 7.96;
P = 0.04 (Warner 1978)
)
8/13 participants (62%)
in the immunotherapy
group and 9/11 par-
ticipants (81%) in the
placebo group (RR 0.75,
95% CI 0.45 to 1.26; P =
0.38 (Glover 1992))
Due to unexplained sta-
tistical heterogeneity, we
did not pool the data
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Participant- or parent-
reported specific symp-
toms of eczema
Follow-up: 12 to 18
months
SCORAD part C mea-
sured as a combination of
2 Visual Analogue Scales
(1 for itch, 1 for sleep
disturbance), each on a
scale from 0, no specific
symptoms, to 10, maxi-
mum specific symptoms
The mean SCORAD part C
score ranged across con-
trol groups from 3.07 to
5.29
The mean SCORAD part
C sleep severity score
ranged across control
groups from 0.8 to 2.31
(Di Rienzo 2014; Novak
2012)
The mean SCORAD part C
score in the immunother-
apy group was on aver-
age 0.74 lower (95% CI -
1.98 to 0.50)
The mean SCORAD part
C sleep severity score in
the immunotherapy group
was on average 0.49
lower (95% CI -1.03 to
0.06)
(Di Rienzo 2014; Novak
2012)
- 339a
(6)
⊕©©©
very lowc
Itch: SCORAD part C itch
severity at the end of
treatment: MD -0.24, 95%
CI -1.00 to 0.52; I² = 0%
for Di Rienzo 2014 and
Novak 2012
Itch severity score: MD -
4.20, 95% CI -3.69 to -4.
71 for Sanchez 2012
Due to unexplained sta-
tistical heterogeneity, we
did not pool the data
Adverse events - any
systemic reaction
Follow-up: 6 to 18
months
Low-risk population RR 0.78 (0.41 to 1.49) 492a
(7)
⊕⊕⊕©
moderated
-
0 per 1000 0 per 1000
(0 to 0)
Medium-risk population
71 per 1000 55 per 1000
(29 to 106)
High-risk population
163 per 1000 127 per 1000
(67 to 243)
Investigator- or physi-
cian-rated global as-
sessment of disease
severity
Follow-up: 1 to 3 years
Low-risk population RR 1.48 (1.16 to 1.88) 286a
(7)
⊕©©©
very lowe
-
0 per 1000 0 per 1000
(0 to 10)
Medium-risk population
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471 per 1000 697 per 1000
(546 to 885)
High-risk population
778 per 1000 1151 per 1000
(903 to 1462)
Investiga-
tor- or physician-rated
eczema severity using a
published scale
Follow-up: 12 to 18
months
The mean SCORAD score
ranged across control
groups from 26.7 to 32.6
(Di Rienzo 2014; Novak
2012; Sanchez 2012)
The mean SCORAD score
in the immunotherapy
group was on average 5.
79 lower (95% CI -7.92
to -3.66)
(Di Rienzo 2014; Novak
2012; Sanchez 2012)
- 435a
(6)
⊕©©©
very lowf
-
Participant or parent-
rated eczema severity
using a published scale
Follow-up: 12 to 18
months
See comment See comment Not estimable 184a
(2)
⊕⊕©©
lowg
SCORAD part C used
as the specific eczema
symptom score (Di
Rienzo 2014; Novak
2012)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; IQR: interquartile range; MD: mean difference; RR: risk ratio; SCORAD: SCORing Atopic Dermatitis.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Assumed risks are based on the total control group risk across all included studies (medium risk population) and the included studies
with the lowest (low risk population) and highest (high risk population) control group risks.
aThe number of total participants did not include those that were lost to follow up. The number of total participants and trials included
those that contributed to narrative synthesis.
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bWe downgraded the quality of the evidence by two levels because of unexplained heterogeneity (serious, -1) and imprecision (serious, -
1). There was significant heterogeneity (I² = 83%) between the estimate of dichotomous effects in two studies (Glover 1992 and Warner
1978), and data were not pooled. The information size was small.
cWe downgraded the quality of the evidence by three levels because of study limitations (serious, -1), imprecision (serious, -1),
and unexplained heterogeneity (serious, -1). Two trials were non-blinded (Di Rienzo 2014; Sanchez 2012). Moderate proportions of
participants were not analysed (losses to follow up). The information size was small. Most subgroups of estimate of treatment effects
were not significant, with high heterogeneity displayed by itch (I² = 98%). We did not pool data from all studies because of different
symptoms and different scoring systems reported.
dWe downgraded the quality of the evidence by one level because of imprecision (serious, -1). The estimate of treatment effect relied
largely on two studies (Novak 2012; Qin 2014). It is unclear whether the estimate obtained from a small number of adverse reactions to
two different dust mite extracts can be generalised. Indeed, data from other populations suggest that specific allergen immunotherapy is
generally associated with a small but significant risk of systemic adverse reactions.
eWe downgraded the quality of the evidence by three levels because of study limitations (serious, -2) and imprecision (serious, -1). The
estimate of treatment effect relied on two non-blinded studies. The information size was small.
fWe downgraded the quality of the evidence by three levels because of study limitations (serious, -2) and imprecision (serious, -1). Two
studies were non-blinded. Moderate proportions of participants were not analysed (losses to follow up). The information size was small.
gWe downgraded the quality of the evidence by two levels because of study limitations (serious, -1) and imprecision (serious, -1). One
study was non-blinded. Moderate proportions of participants were not analysed (losses to follow up). The information size was small.
We did not include analyses of non-published scales in this summary table.
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B A C K G R O U N D
We have listed unfamiliar terms in the glossary of terms in Table
1.
Description of the condition
Atopic eczema (AE) is a chronic inflammatory skin condition
that affects 15% to 30% of children and 2% to 10% of adults
world wide (Odhiambo 2009; Williams 2006). The terms ’atopic
eczema’ and ’atopic dermatitis’ are synonymous. Severe itching
and patches of dry inflamed skin in varying locations depending
on the age of the person characterise this condition (Akdis 2006).
In infants, AE is usually found on the cheeks, forehead, or scalp.
In childhood, AE usually involves the hands, feet, wrists, ankles,
and the creases of the elbows and backs of the knees (Akdis 2006).
In adults, AE causes dry scaly patches and large plaques of thick-
ened (lichenified) skin in the flexural folds; the face and neck; the
upper arms and back; and the backs of the hands, feet, fingers,
and toes (Akdis 2006). Strictly speaking, the term ’atopic eczema’
“should only refer to individuals who have the physical features of
eczema plus evidence of specific immunoglobulin E (IgE) antibod-
ies to common environmental allergens such as house dust mite”
(Johansson 2004). We have used this strict definition throughout
this review unless we have specified otherwise.
Several observations suggest that allergensmay be important causes
of atopic eczema. Firstly, direct exposure of the skin to environ-
mental allergens, including perennial allergens like house dust
mite, and seasonal allergens like pollen has been shown to increase
the severity of atopic eczema (Capristo 2004; Purvis 2005; Schäfer
1999). Secondly, other diseases triggered by allergens are common
in those with atopic eczema. For example, of those children who
develop the condition during the first two years of life, an esti-
mated 50%may develop asthma during subsequent years (Warner
2001). Finally, those with more severe AE have an increased risk
of asthma and allergic rhinitis (Gustafsson 2000; Illi 2004).
Despite the current available topical treatment with emollients;
corticosteroids; calcineurin inhibitors; and other treatments, such
as antibiotics, people with atopic eczema often cannot keep their
condition completely under control. In some cases, the medica-
tions used can cause more harm than benefit (Akdis 2006). There-
fore, considering the atopic background of the disease and its pos-
sible correlation with allergen-triggering factors, some other types
of treatment have been proposed, which include specific allergen
immunotherapy (SIT) (Darsow 2012).
Description of the intervention
Specific allergen immunotherapy (SIT) is a treatment for allergic
disease that involves the administration of an allergen in high doses
in order to induce immune tolerance to that allergen and relieve
symptoms (Calderon 2007). For example, in people with hay fever
who are allergic to grass pollen, SIT may involve treatment with
injections, drops, or tablets of grass pollen over a period of months
in order to relieve symptoms (Calderon 2007; Wilson 2005). Spe-
cific allergen immunotherapy is the only treatment shown to pro-
vide longer-term benefit in allergic diseases after treatment has
stopped (Durham 1999). It has been shown to be an effective
treatment for allergic rhinitis and allergic asthma, although the
treatment carries a risk of severe allergic reaction (Calderon 2007;
CSM report 1986; Wilson 2005).
How the intervention might work
Specific allergen immunotherapy works by inducing changes in
the immune response to the relevant allergen, so that in diseases
caused by an abnormal response to that allergen, there may be an
improvement in symptoms (Allam 2006). The specific immune
changes caused by SIT include an increase in activity of suppressive
components of the immune system (regulatory T cells) and an
increase in antibodies (immunoglobulin G (IgG) antibodies) to
the allergen (Bussmann 2007; Bussmann 2009; Maintz 2007).
The presence of allergic sensitisation in those with AE and the
relationship between AE and other allergic diseases suggest that
allergic immune responses are an important part of the disease
process in AE (Gustafsson 2000; Illi 2004; Warner 2001). It is
therefore plausible that SIT might be able to reduce symptoms
in people with AE by inhibiting abnormal immune responses to
allergens.
Why it is important to do this review
Specific allergen immunotherapy is a disease-modifying treatment
that reduces symptoms in people with other allergic conditions:
allergic rhinitis, allergic conjunctivitis, and asthma (Abramson
2003; Calderon 2007; Dahl 2006; Didier 2007; Penagos 2008).
Hence, SITmight be potentially effective in reducing AE. An eval-
uation of its effects on skin manifestations in the context of ran-
domised controlled trials could provide an alternative treatment
for people with AE.
The plans for this review were published as a protocol ’Spe-
cific allergen immunotherapy for the treatment of atopic eczema’
(Calderon 2010).
O B J E C T I V E S
To assess the effects of specific allergen immunotherapy (SIT),
including subcutaneous, sublingual, intradermal, and oral routes,
compared with placebo or a standard treatment in people with
atopic eczema.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adults and children with atopic eczema (AE) and allergic sen-
sitisation to an inhalant or food allergen. “Allergy needed to be
proven using an objective test such as a positive skin prick test or
high circulating levels of allergen-specific IgE antibody detected
by a specific blood test for allergy called the radioallergosorbent
test. Trials focusing on allergic rhinitis or asthma without eczema
were excluded” (Calderon 2011). Where trials included partici-
pants with and without AE, we only included the trial if the results
for the participants with AE were separately reported.
Types of interventions
High-dose immunotherapy with standardised allergen extracts for
single allergen or mixed allergens administered by the sublingual
(under the tongue), subcutaneous (under the skin), intradermal
(into the skin), or oral route compared with placebo or a standard
treatment, such as emollients, topical corticosteroids, or topical
calcineurin inhibitors. We considered all appropriate allergens at
all doses and all durations of treatment.
Types of outcome measures
Primary outcomes
1. Participant- or parent-reported global assessment of disease
severity at the end of treatment, i.e. the proportion with good or
excellent improvement at this time as reported in the trials
(whether treatment was given for one, two, or three years, or
other duration).
2. Participant- or parent-reported specific symptoms of
eczema, by subjective measures such as itch or sleep disturbance
(SCORing Atopic Dermatitis (SCORAD) part C).
3. Adverse events, such as acute episodes of asthma or
anaphylaxis.
Secondary outcomes
1. Investigator- or physician-rated global assessment of disease
severity at the end of treatment, i.e. the proportion with good or
excellent improvement at this time as reported in the trials
(whether treatment was given for one, two, or three years, or
other duration).
2. Parent- or participant-rated eczema severity assessed using a
published scale (e.g. Patient Oriented Eczema Measure
(POEM)).
3. Investigator- or physician-rated eczema severity assessed
using a published scale (e.g. SCORAD).
4. Use of other medication for treatment of eczema during the
intervention period (e.g. topical/systemic corticosteroids,
calcineurin inhibitors, or oral antihistamines).
5. Validated eczema-related quality of life scores (e.g.
Dermatitis Family Impact Questionnaire, Children’s
Dermatology Life Quality Index) (Lewis-Jones 1995).
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
We searched the following databases up to 21 July 2015:
• the Cochrane Skin Group Specialised Register using the
terms ’(dermatitis or eczema) and (immuno* or allerg*)’;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) 2015, Issue 7, in the Cochrane Library using the
search strategy in Appendix 1;
• MEDLINE via Ovid (from 1946) using the strategy in
Appendix 2;
• EMBASE via Ovid (from 1974) using the strategy in
Appendix 3;
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 4;
• the Global Resource of EczemA Trials. Centre of Evidence
Based Dermatology, accessed at www.greatdatabase.org.uk, using
the terms ’immuno* or allerg*’ in the title or keywords of records
and restricting to included studies only; and
• Web of Science™ (from 2005) using the strategy in
Appendix 5.
Trials registers
We searched the following trials registers up to 3 August 2015
using the terms ’immunotherapy and (eczema or dermatitis)’.
• The International Standard Randomised Controlled Trial
Number (ISRCTN) registry (www.isrctn.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (apps.who.int/trialsearch/).
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• The Ongoing Skin Trials Register (www.nottingham.ac.uk/
ongoingskintrials).
Searching other resources
We created a database of first and last names of authors of po-
tentially eligible studies and searched the Science Citation Index
Expanded (SCI-EXPANDED, 1945 to the present) using these
names in order to identify further relevant studies.
Reference lists
We checked the bibliographies of each included study and of pub-
lished reviews for further reports of relevant trials.
Correspondence
We contacted the primary author of each included study to iden-
tify additional published and unpublished studies. We contacted
allergen immunotherapy product manufacturers to request details
of published or unpublished studies of allergen immunotherapy
that included eczema as an outcome measure.
Conference proceedings
We searched the abstracts of the European Academy of Allergy
and Clinical Immunology and the American Academy of Allergy,
Asthma & Immunology meetings from 2010 to 2015.
Data collection and analysis
Some parts of the methods section of this review uses text that was
originally published in other Cochrane Reviews co-authored by
RB andMC (predominantly Boyle 2012 and Calderon 2011).We
included a ’Summary of findings’ table where we used the Grading
of Recommendations Assessment, Development and Education
(GRADE) approach to assess the quality of the evidence for the
primary and secondary outcomes.
Selection of studies
Two authors, RB and MC or HT, independently checked titles
and abstracts identified from the searches, looked at the full text of
all studies of possible relevance for assessment, and decided which
trials met the inclusion criteria. The authors resolved any disagree-
ments by discussing issues with each other, and the planned re-
course to a third author (HN) for arbitration did not prove nec-
essary. We sought further information from trial authors when
needed to confirm eligibility.
Data extraction and management
Two authors, RB and HT or LM, independently extracted data
from included trials and entered data into a specially designed data
extraction sheet, and the authors met to compare results. MC, RB,
and HT wrote to all authors to request additional information as
required. Two authors, RB and HT or LM, entered the data into
Review Manager (RevMan).
Assessment of risk of bias in included studies
Weassessed anddocumented the risk of bias in the included studies
by concentrating on the following six parameters to assess quality:
random sequence generation, allocation concealment, blinding,
incomplete outcome data, selective outcome reporting, and other
potential sources of bias as specified in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Three authors,
RB, HT, and HN, independently assessed risk of bias: we were
not masked to study details. We met to resolve any disagreements,
and the planned recourse to a fourth author, MC, for arbitration
did not prove necessary.
The ’Risk of bias’ tables, which are part of the ’Characteristics of
included studies’ tables, addressed each domain for each study.
Measures of treatment effect
For continuous data, we calculated individual and pooled statistics
as mean differences (MD) where studies used the same outcome
measure and reported them with a 95% confidence interval (CI)
where possible. For dichotomous outcomes, we expressed results
as a risk ratio (RR) with 95% CI, where possible. We were unable
to express the result for dichotomous outcomes as number needed
to treat (NNT) as we had originally planned.
Unit of analysis issues
We planned to analyse cross-over trials through the use of tech-
niques appropriate for paired designs and data from parallel trials
and cross-over trials as separate subgroups, since cross-over studies
may not be appropriate for immunotherapy studies. Our search
did not identify any cross-over trials.
We planned to list non-randomised controlled studies but did not
discuss them further because we did not identify significant studies
or data from non-randomised controlled studies.
Where studies reported more than one active intervention, we
planned to combine the two active interventions and analyse them
together, but we included no trials with more than one eligible
active intervention. Where studies reported non-parametric statis-
tics, we planned to include these in meta-analyses where possible,
following the guidance of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
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Dealing with missing data
We contacted authors when a paper did not present details about
study design or descriptive statistics for outcomes (mean, standard
deviation (SD)). If the authors did not respondwithin a reasonable
time (six to eight weeks) to at least two separate written requests
for information, we conducted the review based on available in-
formation.
Assessment of heterogeneity
We used the I² statistic to test for heterogeneity and assumed
substantial statistical heterogeneity if the I² was greater than 50%
(Higgins 2002).Weused sensitivity or subgroup analysis to explore
any statistical or clinical heterogeneity (see below). Quantitative
analyses of outcomes were, wherever possible, on an intention-
to-treat basis, i.e. participants were evaluated in the groups to
which they were randomised, rather than according to the actual
treatment that they received.
We gave consideration to the appropriateness of meta-analysis in
the presence of significant clinical or statistical heterogeneity and
used a random-effects model.
Assessment of reporting biases
We planned to use funnel plots to assess publication bias graphi-
cally (if there were sufficient included studies) and Begg and Egger
tests to assess it statistically (Begg 1994; Egger 1997); however, we
did not have a sufficient number of included studies.
Data synthesis
We planned to combine appropriate data from individual studies
in a meta-analysis only if heterogeneity measured by I² was less
than 75% with the use of a random-effects model. Where meta-
analyses were not applicable, we used a narrative synthesis of out-
comes from relevant studies.
Subgroup analysis and investigation of heterogeneity
We planned five a priori subgroup analyses.
1. Immunotherapy type: sublingual and subcutaneous.
2. Allergen type: seasonal inhalant, perennial inhalant, food,
and microbial.
3. Age of participants: up to four years, five to 11, 12 to 17,
and 18 or over.
4. Immunotherapy regimens to be subdivided empirically into
low, intermediate, and high dose therapy according to content of
major allergen per dose (e.g. Phleum p5 for grass, Bet v1 for
birch pollen, Fel d1 for cat, etc.):
i) for subcutaneous immunotherapy, content of major
allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11
mcg per four- to six-weekly maintenance injection doses; and
ii) for sublingual immunotherapy, content of major
allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11
mcg per daily maintenance sublingual dose (or equivalent if
taken less frequently).
5. Severity of AE at randomisation: mild (SCORAD mean
objective score of 0 to 15), moderate (SCORAD mean objective
score of 16 to 40), and severe (SCORAD mean objective score of
greater than 40).
Sensitivity analysis
We planned to undertake sensitivity analysis for the allocation
of missing data by best and worst case analysis. If we had found
significant heterogeneity between studies, we planned to explore
possible reasons for this, which would have included risk of bias
in the included studies. However, we did not perform posthoc
sensitivity analyses because of the small number of studies that
contributed to meta-analyses.
R E S U L T S
Description of studies
See the ’Characteristics of included studies’, ’Characteristics of
excluded studies’, ’Characteristics of studies awaiting classifica-
tion’, and ’Characteristics of ongoing studies’ tables.
Results of the search
The search identified 1550 references from electronic databases
and six additional reports from other sources (three from screen-
ing references of review articles and three from ongoing tri-
als registries), which gave a total of 1556 records (see the Pre-
ferred Reporting Items for Systematic Reviews andMeta-Analyses
(PRISMA) flow diagram in Figure 1). We excluded 1465 refer-
ences based on titles and abstracts. MC or HT and RB selected
91 records for which they screened the full text. We excluded 64
records and listed one as an ongoing study. Overall, 26 reports of
12 separate studies met the inclusion criteria (Di Rienzo 2014;
Galli 1994; Glover 1992; Kaufman 1974; Leroy 1993; Luna-Pech
2013; Novak 2012; Pajno 2007; Qin 2014; Sanchez 2012; Silny
2006; Warner 1978). We contacted the authors of all of the 12
included trials for original data and clarification of methods; we
received further details from the authors or their collaborators for
four trials (Di Rienzo 2014; Novak 2012; Sanchez 2012; Warner
1978).
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Figure 1. PRISMA flow diagram
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Included studies
We included 12 studies, with a total of 733 participants.
Setting
Studies were conducted in specialist allergy centres in the UK
(Glover 1992; Warner 1978), Italy (Di Rienzo 2014; Galli 1994;
Pajno 2007), the USA (Kaufman 1974), Germany (Novak 2012),
Belgium (Leroy 1993), Poland (Silny 2006), Columbia (Sanchez
2012), Mexico (Luna-Pech 2013), and China (Qin 2014).
Participants
Two trials studied adults (Novak 2012;Qin2014), six studied chil-
dren (Di Rienzo 2014; Galli 1994; Glover 1992; Luna-Pech 2013;
Pajno 2007; Warner 1978), and four studied both children and
adults (Kaufman 1974; Leroy 1993; Sanchez 2012; Silny 2006).
Ten studies were restricted to people allergic to Dermatophagoides
pteronyssinus or Dermatophagoides farinae (house dust mites) or
both (Di Rienzo 2014; Galli 1994; Glover 1992; Leroy 1993;
Luna-Pech 2013; Novak 2012; Pajno 2007; Qin 2014; Sanchez
2012; Warner 1978), one study was restricted to people allergic
to house dust mites or grass pollen (Silny 2006), and one study
was restricted to people allergic to a group of unspecified inhalant
antigens (Kaufman 1974).
Interventions
The 12 included studies were all of specific allergen immunother-
apy (SIT). Of these, six trials studied subcutaneous immunother-
apy (SCIT) (Glover 1992; Kaufman 1974; Novak 2012; Sanchez
2012; Silny 2006; Warner 1978), four studied sublingual im-
munotherapy (SLIT) (Di Rienzo 2014; Luna-Pech 2013; Pajno
2007;Qin 2014), one studied intradermal immunotherapy (Leroy
1993), and one studied oral immunotherapy (Galli 1994).
Eight trials compared the intervention with a placebo (Glover
1992; Kaufman 1974; Leroy 1993; Luna-Pech 2013;Novak 2012;
Pajno 2007; Silny 2006; Warner 1978), and four compared the
intervention with a standard treatment (Di Rienzo 2014; Galli
1994; Qin 2014; Sanchez 2012). The duration of treatment was
less than a year in one trial, Leroy 1993, and at least a year in
Di Rienzo 2014, Galli 1994, Glover 1992, Kaufman 1974, Luna-
Pech 2013, Novak 2012, Pajno 2007, Qin 2014, Sanchez 2012,
Silny 2006, and Warner 1978.
Outcomes
With regard to our prespecified primary outcomes, two studies
reported ’Participant- or parent-reported global assessment of dis-
ease severity at the end of treatment’ (Glover 1992;Warner 1978),
six studies reported ’Participant- or parent-reported specific symp-
toms of eczema, by subjective measures’ (Di Rienzo 2014; Glover
1992; Leroy 1993; Novak 2012; Pajno 2007; Sanchez 2012), and
seven studies reported ’Adverse events’ (Di Rienzo 2014; Glover
1992; Novak 2012; Pajno 2007; Qin 2014; Sanchez 2012; Silny
2006).
With regard to our prespecified secondary outcomes, seven stud-
ies reported ’Investigator- or physician-rated global assessment of
disease severity at the end of treatment’ (Di Rienzo 2014; Galli
1994; Kaufman 1974; Leroy 1993; Qin 2014; Sanchez 2012;
Silny 2006), two studies reported ’Parent- or participant-rated
eczema severity assessed using a published scale’ in the form of
SCORingAtopicDermatitis (SCORAD) part C (DiRienzo 2014;
Novak 2012), six studies reported ’Investigator- or physician-rated
eczema severity assessed using a published scale’ (Di Rienzo 2014;
Luna-Pech 2013; Novak 2012; Qin 2014; Pajno 2007; Sanchez
2012), eight studies reported ’Use of other medication for treat-
ment of eczema during the intervention period’ (Glover 1992;
Kaufman 1974; Luna-Pech 2013; Novak 2012; Pajno 2007; Qin
2014; Sanchez 2012; Silny 2006), and one study reported ’Vali-
dated eczema-related quality of life scores’ (Novak 2012).
Three studiesmeasured other outcomes: onemeasured total serum
immunoglobulin E (IgE) levels, specific IgE levels, and skin prick
test results (Glover 1992); another measured specific IgE levels
and other serum inflammatory parameters associated with either
allergic inflammation or its suppression, including eosinophilic
cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R),
interferon gamma (IFN-gamma), or interleukins 4, 5, and 10 (
Silny 2006); and a third measured specific serum IgG4 levels (Qin
2014).
Only two of the five publications that reported outcomes from
the Pajno 2007 study contributed data to the review, because the
other three publications did not report atopic eczema outcomes.
Excluded studies
We rejected the other 64 titles for the following reasons: not a
randomised controlled trial (RCT) (13), not SIT (five), not atopic
eczema (AE) (12), review articles (28), and no appropriate control
(six). The reason we included these articles for the full text review
stage is that from the title or abstract we could not exclude the
possibility that they were RCTs of adults or children with AE
and allergic sensitisation, but after assessment of the full text, we
excluded them.
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Studies awaiting classification
There were no studies awaiting classification.
Ongoing studies
There was one ongoing trial with no outcome data available at the
time of review (see the ’Characteristics of ongoing studies’ table).
The contacts for the trial NCT00310492 did not respond to our
request for further information.
Risk of bias in included studies
Full details are shown in the ’Characteristics of included studies’
tables. Please see the ’Risk of bias’ summary (review authors’ judge-
ments about each ’Risk of bias’ item for each included study, Figure
2).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Random sequence generation
There was a low risk of bias related to generation of randomisation
sequence concealment in six studies, Di Rienzo 2014, Kaufman
1974, Novak 2012, Pajno 2007, Silny 2006, Warner 1978, and
unclear risk in the following six studies: Galli 1994, Glover 1992,
Leroy 1993, Luna-Pech 2013, Qin 2014, and Sanchez 2012.
Allocation
There was a low risk of bias related to allocation concealment in
three studies (DiRienzo 2014; Silny 2006;Warner 1978), high risk
in one study (Kaufman 1974), and unclear risk in eight studies due
to insufficient details provided (Galli 1994; Glover 1992; Leroy
1993; Luna-Pech 2013; Novak 2012; Pajno 2007; Sanchez 2012;
Qin 2014).
Blinding
There was a low risk of bias related to blinding of participants and
personnel in two studies (Glover 1992;Warner 1978), which were
either double blinded or triple blinded; high risk in two studies
(Di Rienzo 2014; Sanchez 2012), which were open label; and
unclear risk in eight studies due to insufficient details provided
(Galli 1994; Kaufman 1974; Leroy 1993; Luna-Pech 2013; Novak
2012; Pajno 2007; Qin 2014; Silny 2006).
There was a low risk of bias related to blinding of outcome assessors
in three studies (Glover 1992; Leroy 1993; Warner 1978); high
risk in two studies (Di Rienzo 2014; Sanchez 2012), which were
open label; and unclear risk in seven studies (Galli 1994; Kaufman
1974; Luna-Pech 2013;Novak 2012; Pajno 2007;Qin 2014; Silny
2006), four ofwhichwere unclear regardingwhether they included
outcome assessors in the double blinding (Kaufman 1974; Novak
2012; Pajno 2007; Silny 2006).
Incomplete outcome data
There was a low risk of bias related to incomplete outcome data in
four studies, Galli 1994, Sanchez 2012, Silny 2006, and Warner
1978, where loss to follow-up rates were low, and high risk in eight
studies where loss to follow up rates were high (up to 51%) or
postrandomisation exclusionswere noted:Di Rienzo 2014,Glover
1992, Kaufman 1974, Leroy 1993, Luna-Pech 2013, Qin 2014,
Novak 2012, and Pajno 2007.
Selective reporting
There was a low risk of bias related to selective reporting in three
studies where the specified outcomes in the methodology were
reported in the results, Novak 2012, Sanchez 2012, Warner 1978,
and unclear risk in nine studies: Di Rienzo 2014, Galli 1994,
Glover 1992, Kaufman 1974, Leroy 1993, Luna-Pech 2013, Pajno
2007, Qin 2014, and Silny 2006.
Other potential sources of bias
There was low risk of bias related to other sources in nine studies
(Galli 1994; Glover 1992; Kaufman 1974; Leroy 1993; Novak
2012; Pajno 2007; Sanchez 2012; Silny 2006;Warner 1978), high
risk in two studies where themanufacturer funded the study either
partly or wholly and the authors were affiliated with the manufac-
turer (Di Rienzo 2014; Qin 2014), and unclear risk in one study
where it was unclear whether the authors were affiliated with the
manufacturer (Luna-Pech 2013).
Effects of interventions
See: Summary of findings for the main comparison Specific
allergen immunotherapy versus no immunotherapy
See Summary of findings for the main comparison for the
main comparison ’specific allergen immunotherapy versus no im-
munotherapy’.
Primary outcomes
1. Participant- or parent-reported global assessment of
disease severity at the end of treatment
One study, Warner 1978, measured this outcome as whether the
eczema was improved, there was no change, or it was worse as
rated by the participants or parents. These data were available
for 20 participants at the end of the treatment (nine active, 11
placebo), with improvement in 7/9 (78%) of the immunotherapy
group and 3/11 (27%) in the placebo group (risk ratio (RR) 2.85,
95%confidence interval (CI) 1.02 to 7.96). Another study,Glover
1992, measured this outcome as whether the eczema was better,
the same, or worse as rated by parents. These data were available
for 24 participants, with improvement in 8/13 (62%) of those in
the active treatment group and 9/11 (81%) in the placebo group
(RR 0.75, 95% CI 0.45 to 1.26). We did not perform meta-
analysis because of high heterogeneity between the two studies (I²
= 83%). The high loss to follow-up rate and as-treated analysis in
the study by Glover 1992 may have contributed to the significant
heterogeneity. The quality of the evidence was low.
2. Participant- or parent-reported specific symptoms of
eczema, by subjective measures
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We used original data shared by the authors of two studies, Di
Rienzo 2014 and Novak 2012, to calculate SCORing Atopic Der-
matitis (SCORAD) part C scores at the end of treatment, and
the components of SCORAD part C, which are itch measured by
Visual Analogue Scales (VAS) and sleep disturbance measured by
VAS, each on a scale from 0 to 10. Meta-analysis, with a total of
184 participants, showed no significant difference in SCORAD
part C (mean difference (MD) -0.74, 95% CI -1.98 to 0.50; I²
= 0%; Analysis 1.1) or severity of sleep disturbance (MD -0.49,
95% CI -1.03 to 0.06; I² = 0%; Analysis 1.1).
The authors of Sanchez 2012 provided original data that showed
subjective symptom scores at the end of the treatment on a scale
of 0 to 100, where higher scores meant more symptoms, and a
component of the symptom score, which measured itching sever-
ity on a scale of 0 to 10, where higher scores also meanmore symp-
toms. These data were available for 60 participants at the end of
the treatment (31 active, 29 placebo), with a mean overall severity
score of 37.3 (95% CI 32.4 to 42.1) in the immunotherapy group
and 80.8 (95% CI 75.8 to 85.7) in the control group (P < 0.001)
and a mean itch severity score of 3.2 (95% CI 2.3 to 4.0) in the
immunotherapy group and 7.5 (95% CI 6.9 to 8.0) in the control
group (P < 0.001). The difference between groups in change in
itch severity score from baseline was also statistically significant
(MD -4.20, 95% CI -3.69 to -4.71).
For itch severity, we did not meta-analyse data from these three
studies because of extreme heterogeneity (I² = 98%), which was
attributable to the open label study of Sanchez 2012.Whenwe ex-
cluded this study from meta-analysis, combined data from Novak
2012 and Di Rienzo 2014 showed no significant difference in
SCORAD part C itch severity (MD -0.24, 95% CI -1.00 to 0.52;
I² = 0%).
One study, Glover 1992, reported symptoms in the form of itch
score presented graphically that showed no significant difference
between the active and placebo groups. One study, Leroy 1993,
reported amean itch score of 2.2 (or 33% reduction frombaseline)
after immunotherapy compared with 2.6 (or 19% reduction from
baseline) in the control group. The authors did not comment on
whether this difference was statistically significant and did not
respond to our request for further data.
Other studies reported insufficient data, such as Pajno 2007, or
did not measure this outcome, such as Galli 1994, Kaufman 1974,
Luna-Pech 2013, Qin 2014, Silny 2006, and Warner 1978.
3. Adverse events
Seven studies reported local or systemic reactions to treatment (Di
Rienzo 2014; Glover 1992; Novak 2012; Pajno 2007; Qin 2014;
Sanchez 2012; Silny 2006).
In addition to individual studies, meta-analysis, with a total of 484
participants, showed no statistically significant increase in risk of
local reactions (RR 1.27, 95% CI 0.89 to 1.81; I² = 25%; Analysis
1.2). Data from seven of the 12 studies contributed to this effect
estimate (Di Rienzo 2014;Glover 1992;Novak 2012; Pajno 2007;
Qin 2014; Sanchez 2012; Silny 2006).
In addition to individual studies, meta-analysis with a total of
492 participants showed no statistically significant increase in risk
of systemic reactions (RR 0.78, 95% CI 0.41 to 1.49; I² = 0%;
Analysis 1.2), with 18 events observed in the immunotherapy
group and 15 in the control group. Data from four of 12 stud-
ies contributed to this effect estimate (Glover 1992; Novak 2012;
Pajno 2007; Qin 2014). However, there were no systemic reac-
tions reported in three studies (Di Rienzo 2014; Sanchez 2012;
Silny 2006).
One study, Pajno 2007, with 48 participants, measured other ad-
verse reactions and showed no statistically significant increase in
risk of tiredness (RR 5.08, 95% CI 0.66 to 39.02; Analysis 1.2)
or headache (RR 2.56, 95% CI 0.11 to 59.75; Analysis 1.2).
Secondary outcomes
1. Investigator- or physician-rated global assessment of
disease severity at the end of treatment
Six studies reported investigator- or physician-rated global assess-
ment of disease severity (Di Rienzo 2014; Galli 1994; Kaufman
1974; Qin 2014; Sanchez 2012; Silny 2006). Meta-analysis, with
262 participants, showed significant improvement in disease sever-
ity (RR 1.48, 95% CI 1.16 to 1.88; I² = 19%; Analysis 1.3).
One study, Leroy 1993, with 24 participants, reported improve-
ment in 70% of all of the participants that used an investigator-
rated index of disease severity at a threshold of 50% improvement.
This was significant between the treatment and the placebo group
(P < 0.003), but there were no separate data for the treatment and
placebo group, so we could not include them in a meta-analysis.
Other studies did not measure this outcome (Glover 1992; Luna-
Pech 2013; Novak 2012; Pajno 2007; Warner 1978).
2. Parent- or participant-rated eczema severity assessed
using a published scale
None of the studies reported participant- or parent-rated eczema
severity using a published scale, except for two studies that we
have mentioned above, Di Rienzo 2014 and Novak 2012, which
recorded SCORAD part C, which we included in this systematic
review as a parent- or participant-rated specific eczema symptom
(MD -0.74, 95% CI -1.98 to 0.50; I² = 0%; Analysis 1.1).
Participant- or parent-rated eczema severity assessed using
a non-published scale
Although this was not a prespecified outcome, we felt it impor-
tant to include. Four studies measured participant- or parent-
rated eczema severity assessed using non-published Visual Ana-
logue Scales (VAS) on a scale of 0 to 10 (0 = no symptoms, 10
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= maximal symptoms). Meta-analysis of two studies (Di Rienzo
2014; Qin 2014), with a total of 158 participants, showed statis-
tically significant lower end-of-treatment VAS scores (MD -1.12,
95% CI -1.92 to -0.32; I² = 0%; Analysis 1.4). We used original
data shared by the authors of one study, Di Rienzo 2014, to con-
duct this analysis.
The other two studies only provided original data listed as il-
lustrative text: Pajno 2007 reported a VAS that measured over-
all eczema symptoms with 10.7% improvement in the treatment
group and 13.1% worsening in the placebo group (P = 0.07), but
the study did not report absolute values. Leroy 1993 reported a
VAS that measured participant general well-being with a signif-
icant improvement in the treatment group (P = 0.008) but not
in the control group, but again, did not report absolute values.
Authors of the latter two studies did not respond to our requests
for original data for inclusion in a meta-analysis.
3. Investigator- or physician-rated eczema severity assessed
using a published scale
Six studies reported ’Investigator- or physician-rated eczema sever-
ity assessed using a published scale’ in the form of SCORAD
(Di Rienzo 2014; Luna-Pech 2013; Novak 2012; Pajno 2007;
Qin 2014; Sanchez 2012). Authors of two studies supplied orig-
inal data for end-of-treatment SCORAD (Novak 2012; Sanchez
2012).Meta-analysis of three trials (Di Rienzo 2014; Novak 2012;
Sanchez 2012), with 244 participants, showed significant im-
provement in end of treatment SCORAD (MD -5.79, 95% CI -
7.92 to -3.66; I² = 0%; Analysis 1.5).
One study, Qin 2014, reported reduction ratios in SCORAD and
classified scores as cure (greater than 90%), marked effect (60%
to 89%), improvement (20% to 59%), and ineffective (less than
19%). The total efficacy (defined as percentage of participants
with change in SCORAD ≥ 60%) was significantly greater in
the specific allergen immunotherapy (SIT) group (77.78%) than
in the control group (53.85%) (P < 0.05) and was included as a
dichotomous ’Investigator- or physician-rated global assessment of
disease severity at the end of treatment’ outcome in ameta-analysis
in this review (RR 1.48, 95% CI 1.16 to 1.88; I² = 19%; Analysis
1.3). Another study, Luna-Pech 2013, found a significant change
in SCORADbetween immunotherapy (-18.4 ± 6.5) and control (-
6.6 ± 4.1) (P = 0.008). This effect was greater for participants with
severe eczema at baseline. A further study, Pajno 2007, suggested
greater SCORAD improvement with the SIT than in controls in
graphical data (P < 0.001), but no numerical data were available.
No data for end of treatment SCORAD scores from these three
studies were available for inclusion in a meta-analysis.
One study, Glover 1992, reported no significant difference in
a non-published scale that measured erythema, lichenification,
and surface damage between the immunotherapy and the placebo
groups. Another study, Galli 1994, reported no significant dif-
ference between treatment groups, using a non-published scale
that measured severity of erythema, vesicles, fissuration, lichenifi-
cation, and itching.
4. Use of other medication for treatment of eczema during
the intervention period
One study, Silny 2006, with 20 participants, reported no statis-
tically significant difference between the treatment groups in the
use of topical steroids for mild to moderate flares of AE (RR 1.33,
95% CI 0.74 to 2.41; Analysis 1.6). Another study, Glover 1992,
reported no significant difference in the use of topical steroids be-
tween the treatment groups. (There were no numerical data for
meta-analysis.) One study, Sanchez 2012, reported a significant
reduction in the use of topical steroids and tacrolimus during one
year of immunotherapy (P = 0.02), but there was no such reduc-
tion in the control group.
Two studies reported the use of systemic steroids for AE. One
study, Kaufman 1974, with 26 participants, required the use of
systemic steroids in 8/16 participants (50%) in the immunother-
apy group and 4/10 participants (40%) in the placebo group (P
= 0.70). Another study, Sanchez 2012, with 60 participants, re-
ported a significant increase in systemic steroid use in 12/29 par-
ticipants (41%) in the control group compared with 4/31 partic-
ipants (13%) in the immunotherapy group (P = 0.02). We did
not perform meta-analysis because of the high heterogeneity (I² =
76%). The reason for high heterogeneity between these two stud-
ies was unclear.
Another study, Novak 2012, with 168 participants, reported a
non-significant 32%difference in themedianAUC(area under the
curve) of medication score, a culmination of topical medication
and overall consumption of systemic medication (19,330 in the
immunotherapy group and28,420 in the placebo group; P =0.08).
These data were not in a format suitable for incorporation into a
meta-analysis.
One study, Pajno 2007, reported a significant decrease in the use of
rescue medications (oral hydroxyzine and topical steroids, respec-
tively) in the immunotherapy group. There were 171 occasions
where rescue medications were used in the immunotherapy group
compared with 346 occasions in the placebo group (P = 0.03). The
rescue medications were used on 93 days in the immunotherapy
group and 158 days in the placebo groups (P = 0.01).
One study, Luna-Pech 2013, reported significantly less use of res-
cue medications (not defined) in the treatment group compared
with the control group, but no details were provided.
Another study, Qin 2014, reported an average daily drug score
(one point for symptomatic use of levocetirizine hydrochloride
tablet, mometasone furoate cream, or mupirocin ointment each
day; and six points for every six-day course of clarithromycin for
superinfection). Average daily drug score was lower in the treat-
ment group (mean 0.5, standard deviation (SD) 0.4) than in the
control group (mean 1.3, SD 0.7) (P < 0.01).
Other studies did not report this outcome (Di Rienzo 2014; Galli
18Specific allergen immunotherapy for the treatment of atopic eczema (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1994; Leroy 1993; Warner 1978). None of the studies reported
the use of oral antihistamines or calcineurin inhibitors as separate
outcomes.
5. Validated eczema-related quality of life scores
One study, Novak 2012, reported a validated eczema-related qual-
ity of life score, the Dermatology Life Quality Index (DLQI), at
the end of treatment. We used original data kindly provided by
the trial authors to calculate DLQI at the end of treatment, which
showed no difference between the treatment groups - a median of
3 (interquartile range (IQR) 1.0 to 8.0) for immunotherapy and
a median of 3.5 (IQR 1.0 to 10.5) for placebo (P = 0.525).
Subgroup analyses
We undertook 16 planned subgroup analyses where data were
available.Wedidnot undertake further sensitivity analyses because
of the small number of trials that contributed data to the analyses.
1. Immunotherapy type: sublingual and subcutaneous.
2. Allergen type: seasonal inhalant, perennial inhalant, food,
and microbial.
3. Age of participants: up to four years, five to 11, 12 to 17,
and 18 or over.
4. Immunotherapy regimens to be subdivided empirically into
low, intermediate, and high dose therapy according to content of
major allergen per dose (e.g. Phleum p5 for grass, Bet v1 for
birch pollen, Fel d1 for cat, etc.):
i) for subcutaneous immunotherapy, content of major
allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11
mcg per four- to six-weekly maintenance injection doses; and
ii) for sublingual immunotherapy, content of major
allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11
mcg per daily maintenance sublingual dose (or equivalent if
taken less frequently).
5. Severity of AE at randomisation: mild (SCORAD mean
objective score of 0 to 15), moderate (SCORAD mean objective
score of 16 to 40), and severe (SCORAD mean objective score of
greater than 40).
First, we analysed our primary outcome measure ’Participant- or
parent-reported global assessment of disease severity at the end of
treatment’. Two studies reported dichotomous outcomes that we
did not combine in meta-analyses because of significant hetero-
geneity (I² = 83%) (Glover 1992; Warner 1978). We did not per-
form subgroup analyses because both studies fell under the same
subgroup categories (subcutaneous route, perennial allergen, and
both children and adults).One study,Warner 1978, showed signif-
icant improvement in 7/9 participants (78%) in the immunother-
apy group compared with 3/11 participants (27%) in the placebo
group (P = 0.04). Another study, Glover 1992, showed significant
improvement in 8/13 participants (62%) in the active group com-
pared with 9/11 (81%) in the placebo group (P = 0.38).
Next, we analysed our primary outcome measure ’Participant- or
parent-reported specific symptoms of eczema, by subjective mea-
sures’ in nine subgroup analyses. We found no evidence that this
outcome differed according to the following.
• Route of immunotherapy: SCORAD part C (subcutaneous:
MD -0.62, 95% CI -2.18 to 0.93) (sublingual: MD -0.94, 95%
CI -3.00 to 1.13) (test for subgroup differences: I² = 0%;
Analysis 2.1). With regard to itch, meta-analysis was not possible
due to extreme heterogeneity (I² = 99%) attributable to the study
of Sanchez 2012. Without this study in the analysis, the test for
subgroup difference between sublingual and subcutaneous
immunotherapies and their controls was not significant (I² =
0%) for sleep disturbance (subcutaneous: MD -0.42, 95% CI -
1.24 to 0.40) (sublingual: MD -0.54, 95% CI -1.27 to 0.19)
(test for subgroup differences: I² = 0%; Analysis 2.2).
• Allergen type: SCORAD part C (seasonal inhalant: MD
not estimable) (perennial inhalant: MD -0.74, 95% CI -1.98 to
0.50; Analysis 2.3) (food: MD not estimable) (microbial: MD
not estimable). With regard to itch, meta-analysis was not
possible due to extreme heterogeneity (I² = 99%) attributable to
the study of Sanchez 2012. Without this study in the analysis,
the test for subgroup differences for seasonal inhalant and
perennial inhalant immunotherapies was not significant (I² =
0%) for sleep disturbance (seasonal inhalant: MD not estimable)
(perennial inhalant: MD -0.49, 95% CI -1.03 to 0.06; Analysis
2.4) (food: MD not estimable) (microbial: MD not estimable).
• Participant age: SCORAD part C (up to four years: MD
not estimable) (five to 11 years of age: MD not estimable) (12 to
17 years of age: MD not estimable) (18 years of age or over:
(MD -0.62, 95% CI -2.18 to 0.93; Analysis 2.5); itch (up to
four years of age: MD not estimable) (five to 11 years of age:
MD not estimable) (12 to 17 years of age: MD not estimable)
(18 years of age or over: MD -0.20, 95% CI -1.05 to 0.64;
Analysis 2.6); or sleep disturbance (up to four years of age: MD
not estimable) (five to 11 years of age: MD not estimable) (12 to
17 years of age: MD not estimable) (18 years of age or over: MD
-0.42, 95% CI -1.24 to 0.40; Analysis 2.7).
• Severity at randomisation using original data from one
study for the outcomes itch and sleep disturbance (Novak 2012).
In the moderate severity subgroup, data were available for 37
participants (23 in the immunotherapy group and 14 in the
placebo group): itch did not differ significantly between groups -
with a median of 1.7 (IQR 0.3 to 3.5) for immunotherapy and
1.7 (IQR 0.5 to 3.7) for placebo (P = 0.96) - nor did sleep
disturbance - with a median of 0.3 (IQR 0.1 to 2.8) for
immunotherapy and 0.5 (IQR 0.3 to 1.5) for placebo (P = 0.53).
In the severe subgroup, data were available for 109 participants
(75 in the active group and 34 in the placebo group): itch did not
differ significantly between groups - with a median of 2.0 (IQR
0.7 to 4.1) for immunotherapy and 2.9 (IQR 1.3 to 5.4) for
placebo (P = 0.22) - nor did sleep disturbance - with a median of
1.1 (IQR 0.4 to 3.3) for immunotherapy and 1.9 (IQR 0.6 to
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5.1) for placebo (P = 0.14). During treatment, we also calculated
the change in itch in the moderate (MD 1.01, 95% CI -1.31 to
3.33) and severe subgroups (MD 0.10, 95% CI -1.38 to 1.58;
Analysis 2.8) and sleep disturbance in the moderate (MD 0.38,
95% CI -1.32 to 2.09) and severe subgroups (MD -0.31, 95%
CI -1.66 to 1.04; Analysis 2.9). We found no significant
difference between the immunotherapy and control groups.
Last, we analysed our primary outcome ’Adverse events’ in six
subgroup analyses. We found evidence that this outcome differed
significantly according to the following:
• route of immunotherapy: local reactions were greater in the
immunotherapy group than the control group by the sublingual
(RR 9.76, 95% CI 1.28 to 74.26) but not the subcutaneous
route (RR 1.18, 95% CI 0.90 to 1.55) (test for subgroup
differences: I² = 76%; Analysis 2.10).
We found no evidence that this outcome differed between the
immunotherapy or control groups according to the following:
• route of immunotherapy: systemic reactions (subcutaneous:
RR 0.82, 95% CI 0.34 to 2.00) (sublingual: RR 0.74, 95% CI
0.29 to 1.89) (test for subgroup differences: I² = 0%; Analysis
2.11);
• allergen type: local reactions (seasonal inhalant: RR not
estimable) (perennial inhalant: RR 1.31, 95% CI 0.81 to 2.13;
Analysis 2.12) (food: RR not estimable) (microbial: RR not
estimable); systemic reactions (seasonal inhalant: RR not
estimable) (perennial inhalant: RR 0.78, 95% CI 0.41 to 1.49;
Analysis 2.13) (food: RR not estimable) (microbial: RR not
estimable); and
• participant age: local reactions (up to four years: RR not
estimable) (five to 11: RR not estimable) (12 to 17: RR not
estimable) (18 years or over: RR 1.37, 95% CI 0.44 to 4.23;
Analysis 2.14); systemic reactions (up to four years: RR not
estimable) (five to 11: RR not estimable) (12 to 17: RR not
estimable) (18 years or over: RR 0.74, 95% CI 0.38 to 1.47;
Analysis 2.15).
There were no data available for other subgroup analyses of our
primary outcomes.
D I S C U S S I O N
Summary of main results
We identified 12 randomised controlled clinical trials of specific
allergen immunotherapy (SIT) for the treatment of atopic eczema
(AE), which included 733 participants with eczema and allergic
sensitisation to an inhalant allergen. The studies were of children
and adult participants allergic to house dust mite, grass pollen, and
other inhalant allergens; and immunotherapy via subcutaneous,
sublingual, oral, and intradermal routes. We judged nine studies
to have a high risk of bias due to high rates of loss to follow up
or postrandomisation exclusions, Di Rienzo 2014, Glover 1992,
Kaufman 1974, Leroy 1993, Luna-Pech 2013, Novak 2012, Pajno
2007, Qin 2014, or non-blinded outcome assessment, Di Rienzo
2014, Sanchez 2012.
For our prespecified primary outcomes ’Participant- or parent-re-
ported global assessment of disease severity at the end of treatment’
(two studies, 44 participants, low quality evidence) and ’Partic-
ipant- or parent-reported specific symptoms of eczema, by sub-
jective measures’ (six studies, 339 participants, very low quality
evidence), SIT is not an effective treatment for AE (Summary of
findings for the main comparison). However, the results for our
secondary outcomes ’Investigator- or physician-rated global assess-
ment of disease activity at the end of treatment’ (seven studies, 286
participants) and ’Investigator- or physician-rated eczema severity
assessed using a published scale (e.g. SCORing Atopic Dermatitis
(SCORAD))’ (six studies, 435 participants) indicated SIT was ef-
fective, although the quality of the evidence was low and very low
for these two outcomes, respectively. Our other secondary out-
comes ’Parent- or participant-rated eczema severity assessed using
a published scale’ (two studies, 184 participants) and ’Validated
eczema-related quality of life scores’ (one study, 168 participants)
showed no difference with SIT.
For our primary outcome ’Adverse events’, SIT was not associated
with increased risk of local (seven studies, 484 participants) or sys-
temic (seven studies, 492 participants, moderate evidence) adverse
reactions. Also, SIT was not associated with an increased need for
topical (one study, 20 participants) or systemic (two studies, 86
participants) corticosteroid use during the studies.
Three studies had more positive findings than the others. One,
Sanchez 2012, reported a marked improvement in participant-
or parent-reported symptoms and smaller but statistically signif-
icant improvements in investigator- or physician-reported global
eczema severity and total SCORAD (a 5.8-point greater improve-
ment) compared with untreated participants. Another, Qin 2014,
reported a significantly greater investigator- or physician-rated
global disease severity, defined as change in SCORAD ≥ 60% in
SIT (77.78%) compared with the control (53.85%) (P < 0.05).
A further study, Luna-Pech 2013, reported a significant change
in investigator- or physician-rated global disease severity through
assessment of SCORAD in SIT (mean -18.4, SD 6.5) compared
with the control (mean -6.6, SD 4.1) (P = 0.008), with a greater
effect in those with severe eczema at baseline. No original data
were available for inclusion in meta-analyses.
Subgroup analyses identified a low confidence of effect that sub-
lingual immunotherapy was associated with more local adverse re-
actions compared with subcutaneous immunotherapy. Other sub-
group analyses did not identify a type of allergen, a participant age,
or a severity of AE at randomisation with a different efficacy or
safety profile, although these analyses were generally inconclusive
due to the limited data available.
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Overall completeness and applicability of
evidence
Overall, we found low quality of evidence that specific allergen
immunotherapy is effective in the treatment of atopic eczema. The
varied disease severity scales and symptom scores used across the
trials generally limited the meta-analyses. In those with compa-
rable data, some outcomes were significant. Wide confidence in-
tervals for many outcome measures reflected relatively small stud-
ies and varied methodologies. Several outcomes were based on
analysis from a single trial, Novak 2012, with a large number of
participants but high loss to follow up. Three trials, Di Rienzo
2014, Qin 2014, Sanchez 2012, had more positive findings than
the others and showed a clear beneficial effect on participant- or
parent-reported eczema symptoms and investigator- or physician-
reported global eczema severity in the form of SCORAD. It is not
clear why the findings of these trials differed, but there was a risk
of detection bias due to lack of blinding of participants or investi-
gators in at least two trials (Di Rienzo 2014; Sanchez 2012). We
found that adverse reaction rates were not significantly increased
with immunotherapy in the included studies, but other evidence
suggests that SIT carries a significantly increased risk of severe al-
lergic reactions (Calderon 2007). While this might suggest that
the allergic sensitisation present in the trial participants is of little
clinical relevance or that the allergen extracts used were of low
potency, it may equally reflect the small number of trials and par-
ticipants that contributed to the adverse events analyses.
Quality of the evidence
Our overall judgement of the quality of the body of evidence
that contributed to the results of the review, using the Grading
of Recommendations Assessment, Development and Education
(GRADE) approach (Higgins 2011), was low. The reasons we
downgraded were relatively few trials and participants, lack of
blinding in at least two trials, wide confidence intervals, moderate
risk of bias with high loss to follow up as the main concern, and
significant heterogeneity between the estimate of treatment effects
for a primary outcome.
Potential biases in the review process
The strengths of this review were the adherence to our published
protocol and the repeated efforts to acquire original data from
study authors in order tomaximise opportunities formeta-analysis
and clarify methodological uncertainties. The limited number of
included studies did not allow formal assessment for publication
bias. We analysed different outcome measures as separate analyses,
which limited the opportunities to pool data fromdifferent studies
that used different outcome assessment tools.
Agreements and disagreements with other
studies or reviews
Three other systematic reviews of SIT for the treatment of AE have
been undertaken. In one review (Bae 2013), the authors identified
eight of the 12 trials included in this review but analysed the data in
a different way, by pooling heterogeneous outcomes ’measured by
any scoring systems’, which may not be appropriate (Tam 2013).
In contrast to our review, they found moderate evidence that SIT
may be an effective treatment for AE both in all participants stud-
ied (odds ratio (OR) for improved eczema 5.35, 95% confidence
interval (CI) 1.61 to 17.77) and in subgroup analyses of partic-
ipants with severe eczema at randomisation (OR 3.13, 95% CI
1.31 to 7.47) and studies that used subcutaneous immunotherapy
(OR 4.27, 95% CI 1.36 to 13.39). The different outcomes in
their review are likely due to the unconventional approaches for
extracting and combining data from the included trials. There was
no registered protocol for their review, so we cannot confirm that
the inclusion criteria and outcome measures were determined a
priori.
In a systematic review that used the GRADE recommendations
(Gendelman 2013), the authors identified five of the nine trials
included in our review, and an additional two that we excluded
(Ring 1982;Werfel 2006). The review did not performmeta-anal-
yses. Similar to our review, they found only weak strength of rec-
ommendations for the use of SIT to treat AE. They also reported
similar methodological shortcomings, including high losses to fol-
low up.
In a similar systematic review on sublingual immunotherapy only
that used the GRADE recommendations (Gendelman 2015), the
authors identified three of the 12 trials included in our review and
an additional two that we excluded (Cadario 2007; Mastrandrea
2000). The review did not perform meta-analyses. Similar to our
study, they found only weak strength of recommendations for the
use of sublingual immunotherapy to treat AE with a large placebo
effect in two studies. They also reported similar methodological
shortcomings, which included lack of blinding, lack of control,
and lack of randomisation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found limited evidence that specific allergy immunotherapy
(SIT) provides a treatment benefit for people with atopic eczema
(AE) compared with placebo or no treatment, but due to method-
ological concerns in the included studies, this form of treatment
cannot be recommended for AE at present.
Implications for research
The evidence to date is inconclusive, so more trials are needed to
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clarify whether SIT is effective for the treatment of atopic eczema.
Further large, well-blinded randomised controlled trials that use
modern high quality allergen formulations with a proven track
record in other allergic conditions and also evaluate patient-re-
ported primary outcome measures are needed. If the treatment
is found to be efficacious, identification of those most likely to
benefit would be of great interest.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Di Rienzo 2014
Methods Randomised, open label, controlled, parallel group trial
Duration of study: 12 months
Participants Country: Italy
Age range: children (5 to 18 years)
Total number: 57
Treatment group n: 30 (63% males)
Control group n: 27 (63% males)
Losses to follow up: 19 (33.3% of total) (7 in the treatment group and 12 in the control
group)
Inclusion criteria
People (1) aged over 5 and less than 18; (2) with clinical history of chronic mild to
moderate AD with no evidence of spontaneous remission at the age of 5 years, with
or without intermittent moderate-severe or persistent mild-moderate rhinoconjunctivi-
tis (Allergic Rhinitis and its Impact on Asthma criteria); (3) with sensitisation to Der-
matophagoides pteronyssinus or Dermatophagoides farinae or both diagnosed by prick test
(wheal diameter greater than 3 mm) and by serum specific IgE; (4) aged over 3 years; (5)
with positive atopy patch test to HDM extracts (a concomitant sensitisation to pollen
allergens without exacerbations of AD during pollination was acceptable); and (6) with
SCORAD baseline greater than 8, but 40 or less
Exclusion criteria
None specified
Interventions Treatment: sublingual immunotherapy of SLITone® (50%Dermatophagoides pteronyssi-
nus and 50% Dermatophagoides farinae standardised extracts) and pharmacological top-
ical or systemic treatment or both as needed
Updosing schedule: none
Maintenance dose/frequency: 200 STU daily
Manufacturer: ALK-Abelló, Milan, Italy
Control: pharmacological topical or systemic treatment or both as needed only
Outcomes • Change in SCORAD from baseline to any postbaseline time point
• Change in VAS 0 to 10 of subjective cutaneous symptoms
• Investigator judgement on efficacy from baseline to any postbaseline time point
• Adverse events
Notes Funding: ALK-Abelló Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer generated the randomisation
list: 1 list into blocks of 10 per each centre
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Di Rienzo 2014 (Continued)
Allocation concealment (selection bias) Low risk The randomisation number was assigned
using a centralised procedure only after
each investigator identified 1 participant
who was eligible for recruitment. Investi-
gators were not aware of the randomisation
sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial was open label (not blinded)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The trial was open label (not blinded)
Incomplete outcome data (attrition bias)
All outcomes
High risk 7 participants (23%) in the treatment
group and 12 in the control group (44%)
were lost to follow up. Postrandomisation
exclusion from analyses were noted
Selective reporting (reporting bias) Unclear risk The outcomes were clearly stated, and the
paper reported results for all of these out-
comes. However, it was unclear if the trial
was registered
Other bias High risk Senior authors listed their affiliations as
the company that manufactures the SLIT
drops, which is a significant conflict of in-
terest. The manufacturer also funded the
study
Galli 1994
Methods Randomised, controlled, parallel group trial
Duration of study: 3 years
Participants Country: Italy
Age range: children (0.5 to 12 years)
Total number: 34
Treatment group n: 16 (43.8% males)
Control group n: 18 (61.1% males)
Losses to follow up: none reported
Inclusion criteria
People (1) with positive (greater than 2+) skin prick tests toDermatophagoides pteronyssi-
nus solutions or positive RAST® for antiDermatophagoides pteronyssinus IgE or both; (2)
with eczema diagnosed according to Hanifin and Rajka’s criteria; and (3) aged between
0.5 to 12 years old
Exclusion criteria
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Galli 1994 (Continued)
None specified
Interventions Treatment: oral hyposensitisation therapy that contained major (Der p I and Der p
II) and minor antigens of Dermatophagoides pteronyssinus in addition to conventional
therapy
Updosing schedule: hyposensitisation therapy was given in increasing dosages up to a
final dose of 250 STU
Maintenance dose/frequency: 3 times per week
Manufacturer: not stated
Control: conventional therapy only
Outcomes • Investigator-rated global assessment of symptom improvement using an
unpublished scale
• Use of other medications for treatment of eczema during the intervention period
Notes Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details were provided
Allocation concealment (selection bias) Unclear risk Insufficient details were provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details were provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details were provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no reported losses to follow up,
and all participants were included in the
analyses
Selective reporting (reporting bias) Unclear risk This was unclear
Other bias Low risk We neither detected nor suspected other
sources of bias
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Glover 1992
Methods Randomised, controlled, parallel group trial
Duration of study: maximum 12 months 6 weeks
Participants Country: UK
Age range: children (5 to 16 years)
Total number: 26
Treatment group n: 13 (69.2% males)
Control group n: 13 (38.4% males)
Losses to followup: 2 (7.7%of total) in the control group (1 refused to continue receiving
injections, and 1 had an adverse reaction)
Inclusion criteria
People (1) with a positive skin prick reaction (wheal greater than 4 mm) to Der-
matophagoides pteronyssinus 1.2% containing the same allergen preparation as used in the
hyposensitising injection; (2) with severe atopic eczema unresponsive to adequate treat-
ment with emollients, mild topical corticosteroids, icthammol paste bandage, systemic
antihistamines, and appropriate elimination diet; and (3) aged between 5 to 16 years old
Exclusion criteria
None specified
Interventions Treatment: subcutaneous injections of tyrosine-adsorbed glycerinated extract of Der-
matophagoides pteronyssinus vaccine
Updosing schedule: progressively increased every 6 weeks from 4, 10, 25, 60, 150 to a
maximum of 400 Noon units
Maintenance dose/frequency: 400 Noon units once monthly
Manufacturer: Migen, Bencard (Brentford, UK)
Control: subcutaneous injections of tyrosine suspension only
Outcomes • Parent-reported global assessment of symptom improvement using diary cards. At
the end of the study, parents were asked whether they thought that their child’s eczema
was the same, worse, or better than at the start of the study
• Adverse events monitoring
• Number of topical steroid courses
• Investigator-reported erythema/lichenification/surface damage score on a non-
published scale
• Total serum IgE (measured by double antibody radioimmunoassay) and specific
IgE to Dermatophagoides pteronyssinus, cat fur, dog hair, mixed glass pollens, hen’s egg,
and cow’s milk with results expressed on a scale from 0 (negative) to 4 (very high)
• Skin prick test to Dermatophagoides pteronyssinus, cat fur, dog hair, mixed grass,
whole egg, and cow’s milk
Notes Funding: Beechams® Pharmaceuticals (supplied materials and funded cost of statistical
analysis)
Risk of bias
Bias Authors’ judgement Support for judgement
33Specific allergen immunotherapy for the treatment of atopic eczema (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Glover 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants were noted as randomly as-
signed. Details of randomisation were not
provided
Allocation concealment (selection bias) Unclear risk Insufficient details were provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was stated as double blind, and
placebo injections were described as indis-
tinguishable in colour and texture from the
active injections and were administered in
the same way
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessor for eczema severity
scores was described as being unaware of
whether the participant received active or
placebo treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were not analysed for 2 out of 13 par-
ticipants in the placebo group who stopped
treatment prematurely
Selective reporting (reporting bias) Unclear risk Insufficient details were provided
Other bias Low risk We neither detected nor suspected other
sources of bias
Kaufman 1974
Methods Randomised, controlled, parallel group trial
Duration of study: minimum of 2 years
Participants Country: USA
Age range: children and adults (2 to 47 years)
Total number: 52
Treatment group n: 25; final treatment group n: 16 (56.2% males)
Control group n: 27; final control group n: 10 (30% males)
Losses to follow up: 26 (50% of total) (9 in the treatment group and 17 in the control
group)
Inclusion criteria
People (1) with atopic dermatitis diagnosed by their paediatrician or internist (diagnosis
was confirmed by physicians in the general dermatology clinic and again in the subspe-
cialty atopic dermatitis clinic - the diagnosis was independently confirmed by a board-
certified dermatologist and allergist, respectively); (2) with uncontrolled atopic dermati-
tis; and (3) with presence of at least 3 positive inhalant skin tests from a group of 19
antigens for scratch testing and skin pigmentation light enough for easy interpretation
of wheat- and flare-type skin reactions
Exclusion criteria
None specified
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Kaufman 1974 (Continued)
Interventions Treatment: subcutaneous injections of water soluble alum-precipitated pyridine-ex-
tracted complex - a mix of appropriate concentrations of inhalant antigens to which the
participant was sensitised, chosen from a panel of 10 inhalant agents
Updosing schedule:
Antigen concentration 10 PNU/ml
Dose (volume in ml)
• 1 (0.10)
• 2 (0.15)
• 3 (0.25)
• 4 (0.40)
• 5 (0.60)
• 6 (0.90)
Antigen concentration 100 PNU/ml
Dose (volume in ml)
• 7 (0.10)
• 8 (0.15)
• 9 (0.25)
• 10 (0.40)
• 11 (0.60)
• 12 (0.90)
Antigen concentration 1000 PNU/ml
Dose (volume in ml)
• 13 (0.10)
• 14 (0.15)
• 15 (0.25)
• 16 (0.40) (every 3 weeks)
• 17 (0.40) (every 3 weeks)
Maintenance dose/frequency: once weekly for the first 16 doses and thereafter 3-weekly
throughout the study period
Manufacturer: Dome Laboratories
Control: subcutaneous injections of buffered saline solution only without antigens
Outcomes • Investigator-rated global assessment of symptom improvement supported by a
scoring system on individual symptoms and signs
• Use of systemic steroids
Notes Funding: Dome Laboratories, West Haven (provided immunotherapy products)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using a flip-
ping coin method
Allocation concealment (selection bias) High risk The randomisation procedure was not con-
cealed from the person who prepared the
study treatment for each participant as it
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Kaufman 1974 (Continued)
was the same nurse who did both proce-
dures; therefore, the allocation sequence
was open to manipulation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was reported that only the clinic nurse
(who allocated and prepared the study
treatments) was aware of treatment alloca-
tion. It was also reported that each partici-
pant only saw the syringe that was used for
them
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear whether outcome assessors
were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 participants (36%) in the treatment
group and 17 (63%) in the control group
were lost to follow up. As-treated analyses
were performed
Selective reporting (reporting bias) Unclear risk Insufficient details were provided
Other bias Low risk We neither detected nor suspected other
sources of bias
Leroy 1993
Methods Randomised, controlled, parallel group trial
Duration of study: 4 months
Participants Country: Belgium
Age range: children and adults (17 to 64 years)
Total number: 24
Treatment group n: 13 (58% males)
Control group n: 11 (55% males)
Losses to follow up: 1 (4.2% of total) participant in the treatment group was withdrawn
because of failure to improve
Inclusion criteria
People with atopic dermatitis (1) diagnosed by the criteria of Hanifin and Rajka; (2)
affecting more than 20% of body surface area and without significant spontaneous
remission during the last 2 years; (3) of at least 2 years duration; (4) aged between 15
to 20 years old; and (5) resistant to environmental treatment and showing rapid release
after discontinuation of systemic corticotherapy with total IgE greater than 20 kU/L and
presence of specific IgE to Dermatophagoides pteronyssinus and positive skin prick test to
that allergen
Exclusion criteria
Other treatments of 1) oral corticodepedence or systemic corticosteroids within the 2
months before the trial; 2) cytokine or immunosuppressive therapy (e.g. cyclosporine)
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Leroy 1993 (Continued)
; or 3) phototherapy of PUVA during the 6 weeks preceding the trial; or other disease
whose treatment could affect the symptoms of AD, i.e. erythroderma; acute cutaneous
infection; or immunodeficiency or hyper IgE syndrome or pregnancy
Interventions Treatment: intradermal injections of autologous specific antibody and a glycerinated
extract of Dermatophagoides pteronyssinus
Maintenance dose/frequency and updosing schedule: twice-weekly injection of 100 µl
allergen-antibody complex solution for the first 3 weeks, thenweekly for the next 9 weeks
and then twice during the 4th month (total amount of 240 µg of specific antibodies and
60 µg of allergens in the intervention group)
Manufacturer: Bencard Ltd, Epsom, Surrey
Control: intradermal injections of the carrier buffer
Outcomes • Independent investigator clinical evaluation using Visual Analogue Scale. Itch was
graded on a 4-point scale based on an interview with the participant
• Proportion with local reactions/flare of dermatitis within 48 hours
• Estimation of drug use, i.e. corticosteroid/antibiotic use
Notes Funding: Baxter Healthcare Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details were provided
Allocation concealment (selection bias) Unclear risk Insufficient details were provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details were provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk It was stated that the study blinded both the
clinician who administered the injections
and the clinician who assessed the partici-
pants
Incomplete outcome data (attrition bias)
All outcomes
High risk Noteddata from thewithdrawnparticipant
was not analysed, and 1 participant who
successfully completed the course of injec-
tions was not included for analysis because
he no longer satisfied the entrance criteria
at the time of the first injection
Selective reporting (reporting bias) Unclear risk This was unclear
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Other bias Low risk We neither detected nor suspected other
sources of bias
Luna-Pech 2013
Methods Randomised, controlled, double blind, parallel group trial
Duration of study: 12 months
Participants Country: Mexico
Age range: children (4 to 10 years)
Total number: 68 participants
Treatment group n: 34; dropout rate = 9% (n: 3)
Control group n: 34; dropout rate = 18% (n: 6)
Inclusion criteria
Moderate to severe AD and monosensitised to Dermatophagoides pteronyssinus
Exclusion criteria
Unknown
Interventions Treatment: sublingual immunotherapy to Dermatophagoides pteronyssinus
Updosing schedule: unknown
Manufacturer: unknown
Control: sublingual placebo tablet
Outcomes • Change in SCORAD
• Rescue medications
• Number to treat in order to gain benefit from the intervention
Notes Funding: none declared
The authors did not respond to our request for further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The abstract provided insufficient details
Allocation concealment (selection bias) Unclear risk The abstract provided insufficient details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial was stated as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear whether outcome assessors
were included in the double blinding
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Luna-Pech 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 9% of participants in the treatment group
and 18% in the placebo group were lost to
follow up. Reasons for these were not avail-
able. It was unclear whether there were pos-
trandomisation exclusions from analyses
Selective reporting (reporting bias) Unclear risk The outcomes were clearly stated, and re-
sults for all of these outcomes were re-
ported. However, it was unclear if the trial
was registered. The abstract may not have
included other outcomes
Other bias Unclear risk It was unclear whether the authors were af-
filiated with the manufacturer
Novak 2012
Methods Randomised, controlled, parallel group trial
Duration of study: 18 months
Participants Country: Germany
Age range: adults (18 to 66 years)
Total number: 168
Treatment group n: 112 (55% males)
Control group n: 56 (50% males)
Losses to follow up: 55 (33% of total) - 37 in the treatment group (11 due to adverse
events - 4 of those adverse events considered likely to be due to study medication; 3
due to protocol violation; 23 due to participant withdrawal, non-compliance, or loss to
follow-up) and 18 in the placebo group (3 due to adverse events - 1 of those adverse
events considered likely to be due to study medication; 2 due to protocol violation; 13
due to participant withdrawal, non-compliance, or loss to follow up)
Inclusion criteria
People with (1) eczema diagnosed by Hanifin and Rajka criteria; (2) at least 2 exacer-
bations of eczema or permanent skin lesions during the past 2 months, aggravation of
eczema by exposure to HDM during the heating period (September to February); (3)
duration of condition > 2 years; (4) positive SPT toDermatophagoides pteronyssinus (Der
p) and Dermatophagoides farinae (Def f ) with a wheal diameter of ≥ 4 mm, a negative
control reaction, and specific IgE for Der p or Der f in a RAST® class of ≥ 3; and (5)
stable environmental control - i.e. people were to have implemented encasing strategies
for bedding and mattresses for > 6 months
Exclusion criteria
(1) Previous specific immunotherapy with HDM; (2) photopheresis within 3 months
prior to the study; (3) immunosuppression within 1 month prior to the study; or (4)
pregnant or nursing women
Interventions Treatment: subcutaneous injections of depigmented, polymerised mite extract
Updosing schedule: increasing progressively every 6 weeks from 2, 5, 20, to 50 DPP
Maintenance dose/frequency: up to 50 DPP every 6 weeks
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Novak 2012 (Continued)
Manufacturer: LETI Pharma GmbH, Germany
Control: subcutaneous injections of tyrosine suspension
Outcomes Primary outcomes
• Total SCORAD scores over the 18-month treatment period, reported as
improvement in AUC of SCORAD
• Use of basic medications over the 18-month treatment period
Secondary outcomes
• DLQI evaluated for the whole treatment period and for the heating period from
September to February
• Adverse reactions
Notes Funding: LETI Pharma GmbH, Germany
The study excluded some participants with premature study termination from analysis
potentially because of non-medical reasons whilst including others in the analysis. The
study authors used imputation for missing data to account for the high loss to follow up
rate during the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random numbers were used
Allocation concealment (selection bias) Unclear risk Insufficient details were provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial was stated as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear whether outcome assessors
were included in the double blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 37 participants (33%) in the treatment
group and 18 (32%) in the placebo group
were lost to follow up. Postrandomisation
exclusion from analyses were noted
Selective reporting (reporting bias) Low risk The outcomes reported were consistent
with those described in the registered trial
Other bias Low risk We neither detected nor suspected other
sources of bias
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Pajno 2007
Methods Randomised, controlled, parallel group trial
Duration of study: 18 months
Participants Country: Italy
Age range: children (5 to 16 years)
Total number: 56
Treatment group n: 28 (53.6% males)
Control group n: 28 (42.8% males)
Losses to follow up: 8 (14.3% of total) (2 in the treatment group due to worsening of
symptoms and 6 in the control group: 1 moved out of the area, 3 were non-compliant
with the protocol, and 2 were lost to follow up)
Inclusion criteria
Children (1) aged between 5 to 16 years old; (2) with a clinical history of chronic AD
without evidence of spontaneous improvement at age 5 years; (3) with a SCORAD
of 8 or greater; (4) with an IgE-mediated sensitisation to HDM assessed by positive
skin prick test (wheal greater than 3 mm) and positive CAP-RAST® assay (class III or
greater); (5) for whom if a positive or suggestive history of food allergy in the previous
years with positive skin tests were reported, fully tolerated those foods at enrolment, as
confirmed by a double blind, placebo-controlled food challenge; and (6) with a FEV
greater than 80% of predicted value
Exclusion criteria
(1) Any previous course of immunotherapy; (2) bronchial asthma requiring regular
treatment with inhaled steroids; (3) acute persistent food allergy; or (4) severe systemic
disorders (e.g. cystic fibrosis, diabetes, coeliac disease) or malignancies
Interventions Treatment: sublingual therapy (vial 3) containing 4.3 ug/mL Der p I and 3.5 ug/mL
Der f I glycerinated solution. The dose reached was 3.3 mcg Der p I and 2.7 mcg Der f
I per week
Updosing schedule: 15 days. 1 drop from the first vial (100 RAST® units/mL) every
day up to 5 drops then repeating the steps with vial 2 (1000 RAST® units/mL) and
then vial 3 (10,000 RAST® units/ mL)
Maintenance dose/frequency: 5 drops (250 mcl) from vial 3 (10,000 RAST® units per/
mL), 3 times a week for 18 months
Manufacturer: not stated
Control: sublingual therapy of placebo solution
Outcomes • VAS 0 to 10 recorded by parent at baseline and 18 months - ’how was the eczema
in the last month?’ scored from 0, no symptoms at all, to 10, very severe symptoms
• The change in SCORAD versus baseline assessed before randomisation and then
after 3, 6, 9, 12, 15, and 18 months of treatment
• The use of medications (1 point for each dose of oral hydroxyzine or topical
steroid (fluticasone ointment) and 2 points for each dose of oral clarithromycin in the
6-day course. The latter was given only in the case of superinfection)
Notes Funding: Stallergenes
Risk of bias
Bias Authors’ judgement Support for judgement
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Pajno 2007 (Continued)
Random sequence generation (selection
bias)
Low risk A computer-generated code was used
Allocation concealment (selection bias) Unclear risk Insufficient details were provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial was stated to be double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear whether outcome assessors
were included in the double blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 8 participants were not included in the
analyses: 6 in the control and 2 in the inter-
vention group. Postrandomisation exclu-
sion from analyses were noted
Selective reporting (reporting bias) Unclear risk This was unclear
Other bias Low risk We neither detected nor suspected other
sources of bias
Qin 2014
Methods Randomised, controlled, parallel group trial
Duration of study: 12 months
Participants Country: China
Age range: adults (18 to 46 years)
Total number: 107
Treatment group n: 58 (56.9% males)
Control group n: 49 (61.2% males)
Losses to follow up: 23 (21% of total) (13 in the treatment group and 10 in the control
group)
Inclusion criteria
(1) Clinical history of chronic AD over 2 years; (2) moderate AD, diagnosed according
to Hanifin and Rajka criteria; and (3) sensitisation toDermatophagoides farinae, assessed
by positive skin prick test (skin wheal area ≥ 50% of the positive control)
Exclusion criteria
(1) Any active, acute, or chronic obstructive pulmonary disease, except for asthma and
allergic rhinitis; (2) forced expiratory volume in 1s≤ 70% of predicted value; (3) people
who had disorders with respect to drug absorption, distribution, metabolism, and excre-
tion; and (4) all contraindications for SLIT or the researchers did not think the person
was suitable for the study
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Qin 2014 (Continued)
Interventions Treatment: sublingual Dermatophagoides farinae drops administered at home plus phar-
macotherapy (i.e. oral levocetirizine hydrochloride and topical mometasone furoate
cream)
Updosing schedule: increasing drops of 1 ug/ml, 10 ug/ml, 100 ug/ml, 333 ug/ml, and
1000 ug/ml in the first 5 weeks
Maintenance dose/frequency: 2 drops of 1000 ug/ml daily
Manufacturer: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd
Control: only pharmacotherapy (i.e. oral levocetirizine hydrochloride and topical
mometasone furoate cream)
Outcomes Follow-up at 1, 3, 6, 9, and 12 months:
• Total efficacy measured as ratio of SCORAD reduction ratio ≥ 60%
• VAS 0 to 10 on overall AD symptoms
• Adverse events documented daily
• Drug score documented daily
• Dermatophagoides farinae-specific serum IgG4 at 1, 6, and 12 months
Notes Funding: none declared
The authors did not respond to our request for further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The paper provided insufficient details
Allocation concealment (selection bias) Unclear risk The paper provided insufficient details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The paper provided insufficient details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The paper provided insufficient details
Incomplete outcome data (attrition bias)
All outcomes
High risk 13 participants (22%) in the treatment
group and 10 (20%) in the placebo group
were lost to follow up. It was unclear
whether there were postrandomisation ex-
clusion from analyses
Selective reporting (reporting bias) Unclear risk The outcomes were clearly stated, and re-
sults for all of these outcomes were re-
ported. However, it was unclear if the trial
was registered
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Qin 2014 (Continued)
Other bias High risk 2 authors listed their affiliations as the com-
pany that manufactures the SLIT drops,
which is a significant conflict of interest
Sanchez 2012
Methods Randomised, open label, controlled, parallel group trial
Duration of study: 12 months
Participants Country: Columbia
Age range: children and adults (3 to 25 years)
Total number: 65
Treatment group n: 32; final treatment group n: 31 (52% males)
Control group n: 33; final control group n: 29 (48% males)
Losses to follow up: 5 (7.7% of total) due to moving out of the area (1 in the treatment
group and 4 in the control group)
Inclusion criteria
People with atopic dermatitis (1) diagnosed by the criteria of Hanifin and Rajka; (2)
of at least 2 years’ duration; (3) aged over 3 years; (4) with a SCORAD baseline over
15; and (5) with IgE sensitisation to Dermatophagoides farinae and Dermatophagoides
pteronyssinus
Exclusion criteria
1) Administration of immune suppressors or biological agents in the last 3 months; 2)
significant improvement of symptoms in the last 6 months; or 3) systemic diseases that
contraindicated the use of immunotherapy
Interventions Treatment: subcutaneous injections of depigmented polymerised mites extract (0.5 ml
Der f/Der p, 50 DPP) and pharmacotherapy
Maintenance dose/frequency and updosing schedule: a first injection of 2 separate re-
fracted doses (0.2 ml and 0.3 ml), then monthly single 0.5 ml doses
Manufacturer: LETI laboratories, Madrid, Spain
Control: pharmacotherapy only
Outcomes • SCORAD at 0, 3, 6, 9, and 12 months
• SS consisting of 3 questions (A. How was the eczema last week?, B. Over the last
week, how much has your skin been a problem in your daily activities or sleep?, C.
How severe was the itching during the last week?); the average score was expressed as a
percentage at 0, 3, 6, 9, and 12 months
• Use of rescue mediations (steroids and topical tacrolimus)
• Adverse effects - local and systemic reactions
• Total IgE and specific IgE and IgG4 levels
Notes Funding: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
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Sanchez 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants were noted as randomly as-
signed, but no details of randomisation
were provided
Allocation concealment (selection bias) Unclear risk Insufficient details were provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial was open label (not blinded)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The trial was open label (not blinded)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant in the treatment group (3%)
and 4 in the placebo group (12%) were lost
to follow up because they moved to other
cities
Selective reporting (reporting bias) Low risk Outcomes were clearly stated with results
reported for all of these outcomes. How-
ever, the trial was not registered
Other bias Low risk We neither detected nor suspected other
sources of bias
Silny 2006
Methods Randomised, controlled, parallel group trial
Duration of study: 12 months
Participants Country: Poland
Age range: children and adults (5 to 40 years)
Total number: 20
Treatment group n: 10 (70% males)
Control group n: 10 (80% males)
Losses to follow up: none reported
Inclusion criteria
People with atopic dermatitis and monovalent sensitisation to airborne allergens (house
dustmites or grass pollens) - confirmed by clinical symptoms, skin prick tests, and specific
serum IgE levels
Exclusion criteria
None specified
Interventions Treatment: subcutaneous injections of aluminium hydroxyzine-adsorbed allergen prepa-
rations with Dermatophagoides pteronyssinus (50%), Dermatophagoides farinae (50%), or
grass pollens (100%)
Manufacturer: Allergopharma-Nexter
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Silny 2006 (Continued)
Control: subcutaneous injections of placebo (0.0125 or 0.125 mg/ml of histamine)
Outcomes • Clinical score (point index of severity and extensiveness of skin inflammation)
• Serum concentration of total and allergen specific IgE
• Serum concentration of immunological parameters, i.e. ECP, sIL-2R, IFN-
gamma, Il-4, Il-5, Il-10
Notes Funding: Allergopharma-Nexter and unspecified university
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk It was stated that the sponsor (Aller-
gopharma-Nexter) undertook random se-
quence generation
Allocation concealment (selection bias) Low risk It was stated that the sponsor (Aller-
gopharma-Nexter) undertook allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial was stated as double blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear whether the study included
outcome assessors in the double blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no reported losses to follow up,
which resulted in all participants included
in the analyses
Selective reporting (reporting bias) Unclear risk This was unclear
Other bias Low risk We neither detected nor suspected other
sources of bias
Warner 1978
Methods Randomised, controlled, parallel group trial
Duration of study: 12 months
Participants Country: UK
Age range: children (5 to 14 years)
Total number: 56
Treatment group n: 28; final treatment group n: 27 (77.7% males)
Control group n: 28; final treatment group n: 24 (75.0% males)
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Warner 1978 (Continued)
Losses to follow up: 5 (8.9% of total) (1 in the treatment group and 4 in the control
group)
Inclusion criteria
People (1) with moderate to severe atopic dermatitis; (2) aged between 5 to 14 years
old; and (3) with a positive bronchial provocation test toDermatophagoides pteronyssinus
defined as a fall in peak expiratory flow rate of greater than 20% from baseline within
20 minutes of challenge
Exclusion criteria
People on (1) long-term oral steroids or (2) who had hyposensitisation in the previous 3
years
Interventions Treatment: subcutaneous injections of tyrosine-absorbed Dermatophagoides pteronyssinus
Updosing schedule: 4, 10, 25, 60, 150, and 400 Noon units - weekly injections for 6
weeks
Maintenance dose/frequency: 400 Noon units every 8 weeks
Manufacturer: Migen (Bencard, UK)
Control: subcutaneous injections of tyrosine suspension only
Outcomes • Participant completed a daily diary card of night cough, night wheeze, day
wheeze, and day activity, graded 0 to 5, and recorded each dose of drugs taken for
asthma. At 2-monthly clinic visits, the diary cards were checked, and the participants
and parents were asked whether the asthma (allergic rhinitis, eczema) was better,
unchanged, or worse
• Adverse events recorded by investigators using participant diary cards
Notes Funding: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed via a num-
bers table
Allocation concealment (selection bias) Low risk A third party (pharmacy) conducted the al-
location concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial authors confirmed that partici-
pants, their parents, study personnel, and
outcome assessors were all blind to treat-
ment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial authors confirmed that partici-
pants, their parents, study personnel, and
outcome assessors were all blind to treat-
ment allocation
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Warner 1978 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was 1 (3.6%) withdrawal from treat-
ment in the active group and 4 (14.3%) in
the control group.We included all available
data in the analyses
Selective reporting (reporting bias) Low risk The trial authors confirmed that they used
no other relevant outcome measures in the
trial
Other bias Low risk We neither detected nor suspected other
sources of bias
AD: atopic dermatitis
AUC: area under curve
CAP-RAST®: immunoCAP Specific IgE blood test
DLQI: Dermatology Life Quality Index
DPP: DePigmented and Polymerize
ECP: eosinophil cationic protein
FEV : forced expiratory volume in 1 second
HDM: house dust mite
IFN: interferon
IgE: immunoglobulin E
IL: interleukin
n: number
PNU: protein nitrogen unit
PUVA: psoralen combined with ultraviolet A
RAST®: radioallergosorbent test
SCORAD: SCORing Atopic Dermatitis
sIL-2R: soluble interleukin 2 receptor
SPT: skin prick test
SS: subjective score
STU: standard therapeutic units
VAS: Visual Analogue Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ariano 2009 This was not about atopic eczema
Brunetti 2005 This was not a randomised controlled trial
Businco 1997 This was not about immunotherapy
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Bussman 2007 This was a review article
Cadario 2007 This was not a randomised controlled trial
Canonica 2009 This was a review article
Compalati 2010 This was a systematic review protocol
D’Souza 1973 This was not about atopic eczema
Darsow 2005 This was a review article
Derkach 2015 There was no appropriate control
Finegold 2009 This was a review article
Gendelman 2011 This was a review article
Gendelman 2013 This was a review article
Gendelman 2014 This was a review article
Gendelman 2015 This was a review article
Horak 2009 This was not a randomised controlled trial
Incorvaia 2009 This was a review article
Jacquemin 1995 This was not about specific allergen immunotherapy
Juji 2003 This was not a randomised controlled trial
Larenas-Linnemann 2008 This was a review article
Larenas-Linnemann 2009 This was a review article
Lee 2015 This was a review article
Leung 2015 This was a review article
Margona 2015 This was a review article
Mastrandrea 2000 This was not a randomised controlled trial
Melamed 2010 This was not about atopic eczema
Mihara 2008 This was a review article
Minelli 2010 This was not about atopic eczema
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Mohapatra 2010 This was a review article
Nahm 2008 This was not a randomised controlled trial
Niebuhr 2007 This was a review article
Niebuhr 2008 This was a review article
Noh 2000 This was not a randomised controlled trial
Novak 2007 This was a review article
Ong 2010 This was a review article
Ozdemir 2009 This was a review article
Panzani 1995 This was not about atopic eczema
Passalacqua 2012 This did not have atopic eczema outcomes separately reported
Pereira 2013 This was a review article
Petrova 2001 This was not a randomised controlled trial
Pons-Guiraud 1986 This was not about atopic eczema
Ring 1982 This was not a randomised controlled trial
Roos 2004 This was a review article
Schiavino 2006 This was not about atopic eczema
Senti 2009 This was not a randomised controlled trial
Shi 2010 There was no appropriate control
Slavyanskaya 2014 There was no appropriate control
Slavyanskaya 2014b There was no appropriate control
Smolkin 2000 This was a review article
Stiller 1993 This was not about immunotherapy
Stiller 1994 This was not about immunotherapy
Strannegard 1982 This was not about immunotherapy
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Tammaro 2009 This was not about atopic eczema
Tonnel 2004 This was not about atopic eczema
Van Wijk 2008 This was a review article
Wen 1992 This was not a randomised controlled trial
Werfel 2006 This was not a randomised controlled trial; it was a dose-response study
Werfel 2007 This was a review article
Werfel 2008 This was a review article
Zachariae 1985 There was no appropriate control
Zheng 2011 There was no appropriate control
Zolkipli 2014 This was not about treatment for atopic eczema
Zolkipli 2014b This was not about treatment for atopic eczema
Zolkipli 2015 This was not about treatment for atopic eczema
The reason we included these articles for the full text review stage is that from the title or abstract, we could not exclude the possibility
that they were randomised controlled trials of adults or children with atopic eczema and allergic sensitisation, but we excluded them
after full text review.
Characteristics of ongoing studies [ordered by study ID]
NCT00310492
Trial name or title Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy
of a 12-month subcutaneous specific immunotherapy with ALK-depot SQ milbenmischung in patients with
atopic dermatitis and proven IgE-mediated sensitization to house dust mites
Methods Randomised, controlled, parallel group trial
Duration of study: 12 months
Participants Country: Germany
Age range: adults (15 to 55 years)
Inclusion criteria
(1) Positive specific IgE to house dust mites; (2) atopic dermatitis according to Hanifin/Rajka; (3) chronic
course of atopic dermatitis; and (4) SCORAD larger than 25 points
Exclusion criteria
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NCT00310492 (Continued)
(1) Erythrodermia; (2) systemic treatment with GCs or immunosuppressive agents in the previous 4 weeks;
(3) history of specific immunotherapy with mites; (4) UV radiation; and (5) group 4 topical corticosteroids
(European classification)
Interventions Treatment: subcutaneous injections with ALK-depot SQ mites
Updosing schedule: 16 injections to 100,000 SQ-U
Manufacturer: ALK-Abelló A/S
Control: placebo injections
Outcomes Primary outcome measures
• Changes from baseline in SCORAD and topical medication consumption
Secondary outcome measures
• Changes from baseline in SCORAD intensity score, Eczema Area Severity Index score, and change in
topical medication consumption
Other outcome measures
• SCORAD extent criteria, index, subjective symptoms, Investigator’s Global Assessment score, oral
rescue medication, exacerbation of atopic dermatitis, DLQI, and treatment expectation questionnaire
Starting date April 2006
Contact information Alexander Kapp; Hanover Medical School
Notes Also registered as EudraCT 2005-004675-37
AD: atopic dermatitis
AE: atopic eczema
APT: atopy patch testing
DLQI: Dermatology Life Quality Index
GCs: glucocorticoids
HDM: house dust mite
HIV: human immunodeficiency virus
IgE: immunoglobulin E
SCORAD: SCORing Atopic Dermatitis
SPT: skin prick test
SQ: standardised quality
SQ-U: standardised quality units
UV: ultraviolet
UVA: ultraviolet A
UVB: ultraviolet B
VAS: Visual Analogue Scale
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D A T A A N D A N A L Y S E S
Comparison 1. Immunotherapy versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant- or parent-reported
specific symptoms of eczema
2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 SCORAD part C 2 184 Mean Difference (IV, Random, 95% CI) -0.74 [-1.98, 0.50]
1.2 Severity of sleep
disturbance
2 184 Mean Difference (IV, Random, 95% CI) -0.49 [-1.03, 0.06]
2 Adverse events 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any local reaction 7 484 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.89, 1.81]
2.2 Any systemic reaction 7 492 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.41, 1.49]
2.3 Tiredness 1 48 Risk Ratio (M-H, Random, 95% CI) 5.08 [0.66, 39.02]
2.4 Headache 1 48 Risk Ratio (M-H, Random, 95% CI) 2.56 [0.11, 59.75]
3 Investigator- or physician-rated
global disease severity
6 262 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.16, 1.88]
4 Participant- or parent-rated
eczema severity using a
non-published scale
2 158 Mean Difference (IV, Random, 95% CI) -1.12 [-1.92, -0.32]
5 Investigator-rated eczema
severity assessed using a
published scale
3 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Total SCORAD 3 244 Mean Difference (IV, Random, 95% CI) -5.79 [-7.92, -3.66]
6 Use of other medications for
eczema
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Planned subgroup analyses: immunotherapy versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant- or parent-reported
specific symptoms of eczema -
SCORAD part C by route of
immunotherapy
2 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Subcutaneous
immunotherapy
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Sublingual
immunotherapy
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Participant- or parent-reported
specific symptoms of eczema -
severity of sleep disturbance by
route of immunotherapy
2 Mean Difference (IV, Random, 95% CI) Totals not selected
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2.1 Subcutaneous
immunotherapy
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Sublingual
immunotherapy
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Participant- or parent-reported
specific symptoms of eczema -
SCORAD part C by allergen
type
2 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Perennial inhalant 2 184 Mean Difference (IV, Random, 95% CI) -0.74 [-1.98, 0.50]
4 Participant- or parent-reported
specific symptoms of eczema -
severity of sleep disturbance by
allergen type
2 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Perennial inhalant 2 184 Mean Difference (IV, Random, 95% CI) -0.49 [-1.03, 0.06]
5 Participant- or parent-reported
specific symptoms of eczema
- SCORAD part C by
participant age
1 Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 18 years or over 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Participant- or parent-reported
specific symptoms of eczema -
itch severity by participant age
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 18 years or over 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Participant- or parent-reported
specific symptoms of eczema -
severity of sleep disturbance by
participant age
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 18 years or over 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Participant- or parent-reported
specific symptoms of eczema
- itch severity by severity at
randomisation
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Moderate (SCORAD
mean objective score 16 to 40)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Severe (SCORAD mean
objective score > 40)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Participant- or parent-reported
specific symptoms of eczema -
severity of sleep disturbance by
severity at randomisation
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Moderate (SCORAD
mean objective score 16 to 40)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Severe (SCORAD mean
objective score > 40)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events: any local
reaction by route of
immunotherapy
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Subcutaneous 5 320 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.90, 1.55]
10.2 Sublingual 2 164 Risk Ratio (M-H, Random, 95% CI) 9.76 [1.28, 74.26]
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11 Adverse events: any systemic
reaction by route of
immunotherapy
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Subcutaneous 5 328 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.34, 2.00]
11.2 Sublingual 2 164 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.29, 1.89]
12 Adverse events: any local
reaction by allergen type
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Perennial inhalant 6 464 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.81, 2.13]
13 Adverse events: any systemic
reaction by allergen type
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Perennial inhalant 6 472 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.41, 1.49]
14 Adverse events: any local
reaction by participant age
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 18 years or over 2 275 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.44, 4.23]
15 Adverse events: any systemic
reaction by participant age
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 18 years or over 2 275 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.38, 1.47]
Analysis 1.1. Comparison 1 Immunotherapy versus control, Outcome 1 Participant- or parent-reported
specific symptoms of eczema.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 1 Immunotherapy versus control
Outcome: 1 Participant- or parent-reported specific symptoms of eczema
Study or subgroup
Favours Im-
munother-
apy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SCORAD part C
Di Rienzo 2014 23 2.1304 (2.599) 15 3.07 (3.4942) 36.2 % -0.94 [ -3.00, 1.13 ]
Novak 2012 98 4.6653 (4.3373) 48 5.29 (4.5845) 63.8 % -0.62 [ -2.18, 0.93 ]
Subtotal (95% CI) 121 63 100.0 % -0.74 [ -1.98, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.24)
2 Severity of sleep disturbance
Di Rienzo 2014 23 0.2609 (0.5408) 15 0.8 (1.3732) 55.9 % -0.54 [ -1.27, 0.19 ]
Novak 2012 98 1.8929 (2.1617) 48 2.31 (2.474) 44.1 % -0.42 [ -1.24, 0.40 ]
Subtotal (95% CI) 121 63 100.0 % -0.49 [ -1.03, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
-4 -2 0 2 4
Favours Immunotherapy Favours Control
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Analysis 1.2. Comparison 1 Immunotherapy versus control, Outcome 2 Adverse events.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 1 Immunotherapy versus control
Outcome: 2 Adverse events
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any local reaction
Di Rienzo 2014 8/30 0/27 1.5 % 15.35 [ 0.93, 254.03 ]
Glover 1992 6/13 6/11 14.8 % 0.85 [ 0.38, 1.88 ]
Novak 2012 44/112 20/56 33.0 % 1.10 [ 0.72, 1.67 ]
Pajno 2007 4/26 0/22 1.5 % 7.67 [ 0.44, 134.99 ]
Qin 2014 3/58 0/49 1.4 % 5.93 [ 0.31, 112.12 ]
Sanchez 2012 17/31 12/29 25.3 % 1.33 [ 0.77, 2.27 ]
Silny 2006 8/10 6/10 22.5 % 1.33 [ 0.74, 2.41 ]
Subtotal (95% CI) 280 204 100.0 % 1.27 [ 0.89, 1.81 ]
Total events: 90 (Immunotherapy), 44 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.99, df = 6 (P = 0.24); I2 =25%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Any systemic reaction
Di Rienzo 2014 0/30 0/27 Not estimable
Glover 1992 0/13 1/11 4.3 % 0.29 [ 0.01, 6.38 ]
Novak 2012 9/112 6/56 43.5 % 0.75 [ 0.28, 2.00 ]
Pajno 2007 2/28 0/28 4.7 % 5.00 [ 0.25, 99.67 ]
Qin 2014 7/58 8/49 47.4 % 0.74 [ 0.29, 1.89 ]
Sanchez 2012 0/31 0/29 Not estimable
Silny 2006 0/10 0/10 Not estimable
Subtotal (95% CI) 282 210 100.0 % 0.78 [ 0.41, 1.49 ]
Total events: 18 (Immunotherapy), 15 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
(Continued . . . )
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(. . . Continued)
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Tiredness
Pajno 2007 6/26 1/22 100.0 % 5.08 [ 0.66, 39.02 ]
Subtotal (95% CI) 26 22 100.0 % 5.08 [ 0.66, 39.02 ]
Total events: 6 (Immunotherapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
4 Headache
Pajno 2007 1/26 0/22 100.0 % 2.56 [ 0.11, 59.75 ]
Subtotal (95% CI) 26 22 100.0 % 2.56 [ 0.11, 59.75 ]
Total events: 1 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 3.93, df = 3 (P = 0.27), I2 =24%
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Analysis 1.3. Comparison 1 Immunotherapy versus control, Outcome 3 Investigator- or physician-rated
global disease severity.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 1 Immunotherapy versus control
Outcome: 3 Investigator- or physician-rated global disease severity
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Di Rienzo 2014 20/23 9/15 22.1 % 1.45 [ 0.93, 2.26 ]
Galli 1994 10/16 11/18 16.7 % 1.02 [ 0.60, 1.74 ]
Kaufman 1974 13/16 4/10 8.3 % 2.03 [ 0.92, 4.50 ]
Qin 2014 35/45 21/39 33.1 % 1.44 [ 1.04, 2.01 ]
Sanchez 2012 22/31 12/29 19.0 % 1.72 [ 1.05, 2.79 ]
Silny 2006 7/10 0/10 0.8 % 15.00 [ 0.97, 231.84 ]
Total (95% CI) 141 121 100.0 % 1.48 [ 1.16, 1.88 ]
Total events: 107 (Immunotherapy), 57 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.17, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Immunotherapy versus control, Outcome 4 Participant- or parent-rated
eczema severity using a non-published scale.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 1 Immunotherapy versus control
Outcome: 4 Participant- or parent-rated eczema severity using a non-published scale
Study or subgroup Immunotherapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Di Rienzo 2014 29 3.414 (2.784) 22 4.59 (2.806) 26.5 % -1.18 [ -2.73, 0.37 ]
Qin 2014 58 6.1 (2.16) 49 7.2 (2.67) 73.5 % -1.10 [ -2.03, -0.17 ]
Total (95% CI) 87 71 100.0 % -1.12 [ -1.92, -0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0060)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Immunotherapy versus control, Outcome 5 Investigator-rated eczema severity
assessed using a published scale.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 1 Immunotherapy versus control
Outcome: 5 Investigator-rated eczema severity assessed using a published scale
Study or subgroup
Favours Im-
munother-
apy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Total SCORAD
Di Rienzo 2014 23 19.6348 (22.5623) 15 27.13 (21.8318) 2.2 % -7.49 [ -21.88, 6.90 ]
Novak 2012 98 27.3227 (17.2621) 48 32.62 (20.6179) 9.9 % -5.30 [ -12.06, 1.46 ]
Sanchez 2012 31 20.9 (4.43) 29 26.7 (4.55) 87.9 % -5.80 [ -8.07, -3.53 ]
Subtotal (95% CI) 152 92 100.0 % -5.79 [ -7.92, -3.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 5.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Immunotherapy versus control, Outcome 6 Use of other medications for
eczema.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 1 Immunotherapy versus control
Outcome: 6 Use of other medications for eczema
Study or subgroup Immunotherapy Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silny 2006 8/10 6/10 1.33 [ 0.74, 2.41 ]
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Analysis 2.1. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 1
Participant- or parent-reported specific symptoms of eczema - SCORAD part C by route of immunotherapy.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 1 Participant- or parent-reported specific symptoms of eczema - SCORAD part C by route of immunotherapy
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Subcutaneous immunotherapy
Novak 2012 98 4.6653 (4.3373) 48 5.29 (4.5845) -0.62 [ -2.18, 0.93 ]
2 Sublingual immunotherapy
Di Rienzo 2014 23 2.1304 (2.599) 15 3.07 (3.4942) -0.94 [ -3.00, 1.13 ]
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Analysis 2.2. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 2
Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by route of
immunotherapy.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 2 Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by route of immunotherapy
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Subcutaneous immunotherapy
Novak 2012 98 1.8929 (2.1617) 48 2.31 (2.474) -0.42 [ -1.24, 0.40 ]
2 Sublingual immunotherapy
Di Rienzo 2014 23 0.2609 (0.5408) 15 0.8 (1.3732) -0.54 [ -1.27, 0.19 ]
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Analysis 2.3. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 3
Participant- or parent-reported specific symptoms of eczema - SCORAD part C by allergen type.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 3 Participant- or parent-reported specific symptoms of eczema - SCORAD part C by allergen type
Study or subgroup Immunotherapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Perennial inhalant
Di Rienzo 2014 23 2.1304 (2.599) 15 3.07 (3.4942) 36.2 % -0.94 [ -3.00, 1.13 ]
Novak 2012 98 4.6653 (4.3373) 48 5.29 (4.5845) 63.8 % -0.62 [ -2.18, 0.93 ]
Subtotal (95% CI) 121 63 100.0 % -0.74 [ -1.98, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 4
Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by allergen type.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 4 Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by allergen type
Study or subgroup Immunotherapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Perennial inhalant
Di Rienzo 2014 23 0.2609 (0.5408) 15 0.8 (1.3732) 55.9 % -0.54 [ -1.27, 0.19 ]
Novak 2012 98 1.8929 (2.1617) 48 2.31 (2.474) 44.1 % -0.42 [ -1.24, 0.40 ]
Subtotal (95% CI) 121 63 100.0 % -0.49 [ -1.03, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 5
Participant- or parent-reported specific symptoms of eczema - SCORAD part C by participant age.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 5 Participant- or parent-reported specific symptoms of eczema - SCORAD part C by participant age
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 18 years or over
Novak 2012 98 4.6653 (4.3373) 48 5.29 (4.5845) -0.62 [ -2.18, 0.93 ]
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Analysis 2.6. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 6
Participant- or parent-reported specific symptoms of eczema - itch severity by participant age.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 6 Participant- or parent-reported specific symptoms of eczema - itch severity by participant age
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 18 years or over
Novak 2012 98 2.7724 (2.5204) 48 2.98 (2.3996) -0.20 [ -1.05, 0.64 ]
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Analysis 2.7. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 7
Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by participant age.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 7 Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by participant age
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 18 years or over
Novak 2012 98 1.8929 (2.1617) 48 2.31 (2.474) -0.42 [ -1.24, 0.40 ]
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Analysis 2.8. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 8
Participant- or parent-reported specific symptoms of eczema - itch severity by severity at randomisation.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 8 Participant- or parent-reported specific symptoms of eczema - itch severity by severity at randomisation
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate (SCORAD mean objective score 16 to 40)
Novak 2012 23 2.5 (3.2927) 14 1.49 (3.605) 1.01 [ -1.31, 3.33 ]
2 Severe (SCORAD mean objective score > 40)
Novak 2012 75 3.0441 (3.3939) 34 2.95 (3.767) 0.10 [ -1.38, 1.58 ]
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Analysis 2.9. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 9
Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by severity at
randomisation.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 9 Participant- or parent-reported specific symptoms of eczema - severity of sleep disturbance by severity at randomisation
Study or subgroup Immunotherapy Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate (SCORAD mean objective score 16 to 40)
Novak 2012 23 1.6571 (2.5785) 14 1.27 (2.5537) 0.38 [ -1.32, 2.09 ]
2 Severe (SCORAD mean objective score > 40)
Novak 2012 75 2.6412 (3.3808) 34 2.95 (3.3225) -0.31 [ -1.66, 1.04 ]
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Analysis 2.10. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 10
Adverse events: any local reaction by route of immunotherapy.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 10 Adverse events: any local reaction by route of immunotherapy
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Subcutaneous
Glover 1992 6/13 6/11 11.5 % 0.85 [ 0.38, 1.88 ]
Novak 2012 44/112 20/56 41.5 % 1.10 [ 0.72, 1.67 ]
Pajno 2007 4/26 0/22 0.9 % 7.67 [ 0.44, 134.99 ]
Sanchez 2012 17/31 12/29 25.3 % 1.33 [ 0.77, 2.27 ]
Silny 2006 8/10 6/10 20.8 % 1.33 [ 0.74, 2.41 ]
Subtotal (95% CI) 192 128 100.0 % 1.18 [ 0.90, 1.55 ]
Total events: 79 (Immunotherapy), 44 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Sublingual
Di Rienzo 2014 8/30 0/27 52.3 % 15.35 [ 0.93, 254.03 ]
Qin 2014 3/58 0/49 47.7 % 5.93 [ 0.31, 112.12 ]
Subtotal (95% CI) 88 76 100.0 % 9.76 [ 1.28, 74.26 ]
Total events: 11 (Immunotherapy), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 4.07, df = 1 (P = 0.04), I2 =75%
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Analysis 2.11. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 11
Adverse events: any systemic reaction by route of immunotherapy.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 11 Adverse events: any systemic reaction by route of immunotherapy
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Subcutaneous
Glover 1992 0/13 1/11 8.3 % 0.29 [ 0.01, 6.38 ]
Novak 2012 9/112 6/56 82.8 % 0.75 [ 0.28, 2.00 ]
Pajno 2007 2/28 0/28 8.9 % 5.00 [ 0.25, 99.67 ]
Sanchez 2012 0/31 0/29 Not estimable
Silny 2006 0/10 0/10 Not estimable
Subtotal (95% CI) 194 134 100.0 % 0.82 [ 0.34, 2.00 ]
Total events: 11 (Immunotherapy), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Sublingual
Di Rienzo 2014 0/30 0/27 Not estimable
Qin 2014 7/58 8/49 100.0 % 0.74 [ 0.29, 1.89 ]
Subtotal (95% CI) 88 76 100.0 % 0.74 [ 0.29, 1.89 ]
Total events: 7 (Immunotherapy), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 2.12. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 12
Adverse events: any local reaction by allergen type.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 12 Adverse events: any local reaction by allergen type
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Perennial inhalant
Di Rienzo 2014 8/30 0/27 2.8 % 15.35 [ 0.93, 254.03 ]
Glover 1992 6/13 6/11 21.8 % 0.85 [ 0.38, 1.88 ]
Novak 2012 44/112 20/56 37.9 % 1.10 [ 0.72, 1.67 ]
Pajno 2007 4/26 0/22 2.7 % 7.67 [ 0.44, 134.99 ]
Qin 2014 3/58 0/49 2.6 % 5.93 [ 0.31, 112.12 ]
Sanchez 2012 17/31 12/29 32.1 % 1.33 [ 0.77, 2.27 ]
Subtotal (95% CI) 270 194 100.0 % 1.31 [ 0.81, 2.13 ]
Total events: 82 (Immunotherapy), 38 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 8.04, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Immunotherapy Favours Control
68Specific allergen immunotherapy for the treatment of atopic eczema (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.13. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 13
Adverse events: any systemic reaction by allergen type.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 13 Adverse events: any systemic reaction by allergen type
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Perennial inhalant
Di Rienzo 2014 0/30 0/27 Not estimable
Glover 1992 0/13 1/11 4.3 % 0.29 [ 0.01, 6.38 ]
Novak 2012 9/112 6/56 43.5 % 0.75 [ 0.28, 2.00 ]
Pajno 2007 2/28 0/28 4.7 % 5.00 [ 0.25, 99.67 ]
Qin 2014 7/58 8/49 47.4 % 0.74 [ 0.29, 1.89 ]
Sanchez 2012 0/31 0/29 Not estimable
Subtotal (95% CI) 272 200 100.0 % 0.78 [ 0.41, 1.49 ]
Total events: 18 (Immunotherapy), 15 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 14
Adverse events: any local reaction by participant age.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 14 Adverse events: any local reaction by participant age
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 18 years or over
Novak 2012 44/112 20/56 87.1 % 1.10 [ 0.72, 1.67 ]
Qin 2014 3/58 0/49 12.9 % 5.93 [ 0.31, 112.12 ]
Subtotal (95% CI) 170 105 100.0 % 1.37 [ 0.44, 4.23 ]
Total events: 47 (Immunotherapy), 20 (Control)
Heterogeneity: Tau2 = 0.34; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Immunotherapy Favours Control
70Specific allergen immunotherapy for the treatment of atopic eczema (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.15. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 15
Adverse events: any systemic reaction by participant age.
Review: Specific allergen immunotherapy for the treatment of atopic eczema
Comparison: 2 Planned subgroup analyses: immunotherapy versus control
Outcome: 15 Adverse events: any systemic reaction by participant age
Study or subgroup Immunotherapy Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 18 years or over
Novak 2012 9/112 6/56 47.8 % 0.75 [ 0.28, 2.00 ]
Qin 2014 7/58 8/49 52.2 % 0.74 [ 0.29, 1.89 ]
Subtotal (95% CI) 170 105 100.0 % 0.74 [ 0.38, 1.47 ]
Total events: 16 (Immunotherapy), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Glossary of unfamiliar terms
Term Definition
Anaphylaxis A serious, life-threatening allergic reaction
Fissuration Formation of tears in the skin
Intradermally Into the skin (dermis), below the epidermis
Lichenification Thickening and hardening of the skin
Monovalent 1 kind of antibody
Perennial Long-lasting continually
Photopheresis A form of apheresis and photodynamic therapy
Sublingual Under the tongue
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Table 1. Glossary of unfamiliar terms (Continued)
Vesicles Fluid-filled cavities
A P P E N D I C E S
Appendix 1. CENTRAL (the Cochrane Library) search strategy
#1 (atopic dermatitis)
#2 (atopic eczema)
#3 (neurodermatitis)
#4 (eczema)
#5 MeSH descriptor Dermatitis explode all trees
#6 MeSH descriptor Eczema explode all trees
#7 MeSH descriptor Neurodermatitis explode all trees
#8 MeSH descriptor Dermatitis, Atopic explode all trees
#9 (dermatitis)
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 (besnier* prurigo)
#12 (season* or spring or summer or perennial or pollen or grass* or birch or tree* or weed*)
#13 (mite* or dust* or cat* or dog* or bacteri* or fung* or food* or egg* or peanut* or milk)
#14 (dematophagoides or allergen* or poacea or malassezia or staphylococcus aureus)
#15 MeSH descriptor Pyroglyphidae explode all trees
#16 MeSH descriptor Allergens explode all trees
#17 MeSH descriptor Pollen explode all trees
#18 MeSH descriptor Poaceae explode all trees
#19 MeSH descriptor Malassezia explode all trees
#20 MeSH descriptor Staphylococcus aureus explode all trees
#21 MeSH descriptor Desensitization, Immunologic explode all trees
#22 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#10 OR #11)
#24 (desensitization or immunotherapy or immunomodulatory or hyposensitisation)
#25 (immune therapy) or (immunologic response) or (dose response relationship)
#26 MeSH descriptor Immunotherapy explode all trees
#27 MeSH descriptor Dose-Response Relationship, Immunologic explode all trees
#28 (specific and allergen and immunotherapy)
#29 (#21 OR #24 OR #25 OR #26 OR #27 OR #28)
#30 (#23 AND #22 AND #29)
72Specific allergen immunotherapy for the treatment of atopic eczema (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. Medline (Ovid) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (humans and animals)).sh.
10. 8 not 9
11. exp Eczema/ or eczema.mp.
12. exp Dermatitis, Atopic/
13. atopic eczema.mp.
14. atopic dermatitis.mp.
15. exp Dermatitis/
16. neurodermatitis.mp. or Neurodermatitis/
17. (besnier$ and prurigo).mp.
18. (season$ or spring or summer or perennial or pollen or grass$ or birch or tree$ or weed$).mp.
19. (mite$ or dust$ or cat$ or dog$ or bacteri$ or fung$ or food$ or egg$ or peanut$ or milk).mp.
20. dermatophagoides.mp. or exp Pyroglyphidae/
21. allergens.mp. or exp Allergens/
22. exp Pollen/ or pollen.mp.
23. poacea.mp. or Poaceae/
24. Malassezia.mp. or exp Malassezia/
25. exp Staphylococcus aureus/ or staphylococcus aureus.mp.
26. exp Desensitization, Immunologic/ or desensitization.mp.
27. immunotherapy.mp. or exp Immunotherapy/
28. immunomodulatory.mp.
29. immune therapy.mp.
30. immunologic response.mp.
31. hyposensitisation.mp.
32. exp Dose-Response Relationship,Immunologic/
33. dose response relationship.mp.
34. specific allergen immunotherapy.mp.
35. 11 or 16 or 13 or 17 or 12 or 15 or 14
36. 25 or 21 or 20 or 22 or 18 or 24 or 19 or 23
37. 27 or 33 or 32 or 28 or 26 or 30 or 29 or 31 or 34
38. 36 and 35 and 37 and 10
[1-10: CochraneHighly Sensitive Search Strategy for identifying randomized trials inMEDLINE: sensitivity- and precision-maximizing
version (2008 revision)]
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Appendix 3. EMBASE (Ovid) search strategy
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp.
6. (singl$ adj blind$).mp.
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. eczema.mp. or exp ECZEMA/
15. exp DERMATITIS/ or dermatitis.mp.
16. atopic dermatitis.mp. or exp atopic dermatitis/
17. atopic eczema.mp.
18. neurodermatitis.mp. or exp NEURODERMATITIS/
19. besnier$ prurigo.mp.
20. (season$ or spring or summer or perennial or pollen or grass$ or birch or tree$ or weed$).mp.
21. (mite$ or dust$ or cat$ or dog$ or bacteri$ or fung$ or food$ or egg$ or peanut$ or milk).mp.
22. dermatophagoides.mp. or exp DERMATOPHAGOIDES/
23. pyroglyphidae.mp. or exp PYROGLYPHIDAE/
24. allergens.mp. or exp allergen/
25. exp POLLEN/ or pollen.mp.
26. poaceae.mp. or exp POACEAE/
27. poacea.mp.
28. exp MALASSEZIA/ or malassezia.mp.
29. exp Staphylococcus aureus/ or staphylococcus aureus.mp.
30. exp desensitization/
31. immunotherapy.mp. or exp IMMUNOTHERAPY/
32. immunomodulatory.mp.
33. immune therapy.mp. or exp immunotherapy/
34. immunologic response.mp.
35. hyposensitisation.mp.
36. dose response relationship.mp.
37. exp dose response/
38. specific allergen immunotherapy.mp.
39. 14 or 15 or 16 or 17 or 18 or 19
40. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
41. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
42. 13 and 39 and 40 and 41
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Appendix 4. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
ORMH DOGS ORMH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Words] and (dermatitis
or eczema or eccema) [Words]
In LILACS we searched using the Controlled clinical trials topic-specific query filter.
Appendix 5. Web of Knowledge search strategy
We searched the Science Citation Index Expanded (SCI-EXPANDED) 2005 to present
Topic=(eczema)
Refined by: Topic=(trial) AND Topic=(specific allergen immunotherapy)
Databases=SCI-EXPANDED Timespan=2005-to present
OR
Topic=(eczema)
Refined by: Topic=((randomised controlled trial) or (randomized controlled trial)) AND Topic=(immuno*)
Databases=SCI-EXPANDED Timespan=2005-to present
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HT and LM joined as a co-authors.
Types of interventions: we specified allergen formulations as standardised allergen extracts for single allergen or mixed allergens and
included intradermal and oral routes of immunotherapy because of recent evidence that these routes may be effective for allergen
immunotherapy in general (Anagnostou 2014; Rotiroti 2012).
Types of outcome measures: we clarified the primary outcome ’Participant- or parent-reported specific symptoms of eczema’ by
subjective measures such as itch and sleep disturbance (SCORing Atopic Dermatitis (SCORAD) part C).
Types of outcome measures: although not one of our prespecified outcomes, we analysed ’Participant- or parent-rated eczema severity
assessed using a non-published scale’ because we thought it was important to include it as a subcategory. Six studies reported this
outcome in the form of Visual Analogue Scales.
Types of outcome measures: for consistency, we added ’physician-rated’ to the third secondary outcome.
Measures of treatment effect: we amended the measure of treatment effect in continuous data to be expressed as mean differences
where possible. We planned to express dichotomous outcomes as number needed to treat (NNT), where appropriate, with a 95%
confidence interval (CI) and the baseline risk to which it applies but did not because we identified no suitable findings to which a NNT
might be applied, since the review findings were either negative or inconclusive.
Unit of analysis issues: we planned to use techniques appropriate for paired designs and data from parallel trials and cross-over trials as
separate subgroups to analyse cross-over trials, since cross-over studies may not be appropriate for immunotherapy studies. Our search
did not identify any cross-over trials.
We did not list non-randomised controlled studies because we did not identify significant studies or data from non-randomised
controlled studies.
Where studies reported more than one active intervention, we planned to combine the two active interventions and analyse them
together, but we included no trials with more than one eligible active intervention. Where studies reported non-parametric statistics,
we planned to include these in meta-analyses where possible, following the guidance of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). However, there were no relevant studies.
Assessment of reporting biases: we planned to use funnel plots to assess publication bias graphically (if there were sufficient included
studies) and to use Begg and Egger tests (Begg 1994; Egger 1997) to assess it statistically; however, we did not have a sufficient number
of included studies.
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Sensitivity analysis: we planned to undertake sensitivity analysis for the allocation of missing data by best and worst case analysis. If
we had found significant heterogeneity between studies, we planned to explore possible reasons for this, which would have included
risk of bias in the included studies. However, we did not perform posthoc sensitivity analyses because of the small number of studies
that contributed to meta-analyses.
Appendices: we updated the search strategy for ongoing trial databases to identify relevant trials.
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